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AF Atrial fibrillation 
CCS Causative Classification System  
CE Cardioembolism  
CI Confidence interval  
CISS Chinese Ischemic Stroke Subclassification 
CNS Central nervous system 
CT Computed tomography 
DVT deep vein thrombosis 
DWI Diffusion-weighted imaging 
ECG Electrocardiography 
GI Gastrointestinal  
HR Hazard ratio  
LAA Large artery atherosclerosis 
ICAD Intracranial atherosclerotic disease 
ICD-10 International Classification of Diseases, Tenth Revision 
ICH Intracerebral hemorrhage 
MRI Magnetic resonance imaging 
mRS Modified Rankin scale 
 
 
NIHSS National Institutes of Health Stroke Scale 
NORSTROKE Norwegian Stroke Research Registry 
OR Odds ratio 
SOE Stroke of other determined etiology 
SUE: Stroke of undetermined etiology  
SVO Small vessel occlusion 
TIA Transient ischemic attack 
TOAST Trial of Org 10172 in Acute Stroke Treatment 
tPA Tissue plasminogen activator 
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Ischemic stroke survivors are at high risk of experiencing new or re-expressed focal 
neurological symptoms. This may be due to a recurrent stroke or due to other medical 
conditions, known as stroke mimics. Long-term outcomes after ischemic stroke are 
scarcely studied. In addition, distinguishing recurrent stroke from stroke mimics is 
challenging. Admissions with stroke mimics are resource-consuming and may be 
troublesome for the patients. Knowledge on recurrence, its associated factors, 
mortality and stroke mimics after ischemic stroke is of value in clinical decision-
making.   
The present study investigated incidence, predictors and impact of recurrent stroke in 
a hospital-based ischemic stroke population. In addition, we investigated the burden 
of stroke mimics after ischemic stroke.  
This thesis is based on a hospital-based cohort of patients registered in the Norwegian 
Stroke Research Registry (NORSTROKE) at the stroke unit at the Department of 
Neurology, Haukeland University Hospital. A total of 1874 surviving patients who 
were admitted with ischemic stroke or transient ischemic attack (TIA) between July 
1, 2007, and December 31, 2013 were followed for new hospital admissions with 
recurrent ischemic stroke/TIA or stroke mimics.  
The 30-day recurrence rate was 1.8%. Patients with large artery atherosclerosis and 
stroke of other etiology had increased risk of 30-day recurrence. The long-term 
recurrence rates were modest, being 5.4% and 11.3% at 1 and 5 years respectively. 
Hypertension, prior symptomatic stroke, chronic infarcts on MRI and increasing age 
were independently associated with long-term recurrence. Recurrence more than 
doubled the all-cause mortality. Stroke mimics were more common than recurrence 
after ischemic stroke or TIA. Stroke mimics were multi-etiological and unspecific 
diagnoses were most frequent directly after index stroke.  
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Stroke, or the ancient Hippocratic concept of “acute brain suffering”, has been 
recognized for millennia.2 However, the epidemiological concepts of stroke and other 
cardiovascular diseases have emerged merely during the last 70 years. While Keith et 
al. noted an association between severely elevated blood pressure and 
cerebrovascular disease in 1928,3  the industrialized world was clueless about why 
cardiovascular disease was the main cause of death in mid-twentieth century. As U.S. 
President Franklin D. Roosevelt died in 1945 because of hemorrhagic stroke, the 
National Heart Act was created due to the incomprehension of cardiovascular causes. 
Subsequently, the Framingham Heart Study (FHS) was initiated.4, 5 This 
epidemiological study, which is still ongoing, provided consequential insights by 
identificating the now established risk factors associated with coronary heart disease 
and cerebrovascular disease.6, 7 Preventive strategies focusing on the identified risk 
factors such as smoking, hypertension and hypercholesterolemia have caused a major 
reduction in ischemic stroke incidence and cardiovascular mortality in industrialized 
countries over the last decades.8-10 This progress means that people live longer. 
According to United Nations, the population aged 60 or above is increasing by 3 % 
each year.11 Since ischemic stroke is endemic in people over 60, the absolute number 
of ischemic strokes is anticipated to rise with increasing life-expectancy, mainly due 
to an increase in recurrent ischemic strokes.12 
Recurrent ischemic stroke accounts for around 30% of all strokes.13 Still, the burden, 
mortality and risk factors of recurrent stroke are not sufficiently explored. In a 
systematic review from 2009, Norway was listed as a country with no data on stroke 
incidence trends.8 In fact, the Norwegian Cardiovascular Disease Registry was 
established as recently as 2012.14 Furthermore, recurrent ischemic stroke increases 
morbidity and mortality.15 Rapid hospitalization with suspected recurrence represents 
an opportunity for reducing additional neurological deficits by effective acute 
interventions. However, the occurrence of new neurological symptoms in ischemic 
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stroke survivors may be caused by other diseases than stroke. Such conditions, 
labeled as stroke mimics, are unexplored in patients with prior stroke. 
Current epidemiological data is valuable in order to assess temporal trends of 
diseases, evaluate effects of preventive measures and identify factors associated with 








Stroke, including ischemic stroke, was previously considered purely as a clinical 
syndrome defined by rapidly developing neurological symptoms of presumed 
vascular origin lasting at least an arbitrary period of 24 hours.16 Development of 
diagnostic modalities and effective acute therapies of acute brain ischemia over the 
last decades, have led to the various tissue-based definitions. Ischemic stroke is now 
defined by the American Stroke Association and others as “an episode of 
neurological dysfunction caused by focal cerebral, spinal or retinal infarction”.17 The 
definition of infarction is “cell death attributable to ischemia” found by pathological 
studies, imaging or other objective evidence, or clinical evidence of central nervous 
system (CNS) ischemia lasting ≥24 hours with exclusion of other possible etiologies. 
This definition integrates evident vascular CNS-injury with clinical cases where 
current investigative methods of brain injury are inadequate or not feasible.  
For this doctoral thesis, a similar definition of ischemic stroke was adopted from the 
Baltimore-Washington Cooperative Young Stroke Study.18 The study defined 
ischemic stroke as an episode of neurologic deficit lasting >24 hours, or clinical 
symptoms <24 hours where magnetic resonance imaging (MRI) or computed 
tomography (CT) showed infarctions related to the clinical findings.  
 
Transient ischemic attack 
Definition 
Clinical observations of transient and usually short-lasting neurological deficits of 
presumed ischemic episodes, led to the concept of transient ischemic attack (TIA) of 
the central nervous system. A brief episode of cerebral ischemia was thought to cause 
no brain damage visible by microscopy on autopsy if the patients were left with little 
or no deficits.19, 20 While it was evident that the typical TIA episode was of brief 
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duration and usually lasting minutes, still, as for ischemic stroke, an arbitrary 24-hour 
definition was proposed in 1961.19 In 1975, when this 24-hour definition was adapted 
by the National Institutes of Health committee, the definition of TIA was the 
following: “…episodes of temporary and focal cerebral dysfunction of vascular 
origin, which are variable in duration, commonly lasting from 2 to 15 minutes, but 
occasionally lasting as long as a day (24 hours). They leave no persistent neurological 
deficit.“21 The subsequent adaption of imaging techniques in the following decades 
changed the underlying hypothesis of TIA, as it was evident that there was poor 
correlation between the duration of neurological symptoms and evidence of injury of 
the brain tissue.20 Several studies have demonstrated that 30% to 50% of TIAs 
defined by the 24-hour definition display brain injury on diffusion weighted magnetic 
resonance imaging (DWI-MRI).22 Accordingly, the current definition of TIA is now 
tissue-based: “…focal arterial ischemia with transient symptoms (lasting <24 hours) 
and without evidence of infarction by pathology or imaging should be considered a 
TIA”.17 The same definition of TIA was used for this doctoral thesis. 
 
Ischemic stroke incidence 
Incidence is a risk estimate, or the probability of developing a disease in a population 
over a specified time period. Globally, there were 13.7 million new stroke cases in 
2016, with large variations between countries.9 An individual’s global lifetime risk of 
stroke from the age of 25 years and onwards is recently estimated to be 25%, with 
large global variations.23  
In 2018, there were registered 11.176 patients with ischemic stroke and 6208 patients 
with TIA in Norway.24 Ischemic stroke incidence has declined substantially the last 
five decades in high-income countries.8, 9 This change is also evident in the 
Norwegian population where the age-adjusted standardized stroke incidence rate 
decreased by 8.1% from 2012 to 2016, and for TIA by 13.6% in the same period.25 
 
 
The Global Burden of Disease Study reported an 8% decline of the global- and 18.6% 
of the Norwegian age-standardized stroke incidence from 1990 to 2016.9 Changes in 
stroke incidence is a result of changes in risk factors and stroke prevention 
strategies.26, 27  
 
Ischemic stroke mortality 
Stroke is the second leading cause of death worldwide and was responsible for 11.8% 
of all deaths in 2013.28, 29 Of the 6.5 million deaths from stroke in 2013, 51% were 
due to ischemic stroke.30 Assessment of ischemic stroke mortality is complex due to 
inclusion of hemorrhagic stroke in many epidemiological studies on mortality, as well 
as the use of different mortality measures (e.g. cause-specific mortality vs all-cause 
mortality) across studies. Up to 75% of all deaths within the first year after stroke 
occur during the first three months, but inclusion of intracerebral hemorrhages in 
these studies inflates early mortality.31-35  
 
Early case fatality rate 
The early case fatality rate is the proportion of patients that die shortly after an event, 
in this case ischemic stroke, regardless of the death cause. The time period after the 
event to early death is usually defined as up to 28-30 days.9, 36 Early case fatality after 
ischemic stroke ranged from 13–23% in high-income countries between the years 
2000 and 2008.8 Early case fatality after ischemic stroke declined by about 1% per 
year in high -income countries between the years 1970 and 2008, although with 







The clinical and neurological consequences of ischemic stroke are directly associated 
with mortality during the first week after stroke onset.38, 39 Mortality after the first 
week is largely due to complications of stroke, like infections, venous 
thromboembolism or other systemic medical complications.29, 37, 40 In 2016 in 
Norway, a total of 1927 people died due to a stroke; 401 of which were ischemic, 446 
hemorrhagic and 1080 unspecified.25 Cause-specific mortality after ischemic stroke 
has declined substantially over the last decades.29, 37, 40 This is clearly evident in the 
Norwegian population, where the age-standardized stroke mortality rate declined by 
25% just from 2012 to 2016.25. While cardiovascular diseases were responsible for 
more than half of all deaths in Norway in the 1960s and -70s, this proportion was 
halved in 2017.41 And for the first time, cancer was the leading cause of death in 







Ischemic stroke patients have increased long-term mortality compared to stroke-free 
individuals.42, 43 Functional status in stroke survivors is a strong predictor of long-
term mortality.44 In a Norwegian study, 86.5% of stroke patients had died during the 
12-year follow-up period.45 Studies on long-term mortality after ischemic stroke are 
scarce. In addition, differences in study design and populations makes evaluation of 
long-term mortality difficult.  
 
Etiology and classification of ischemic stroke and TIA 
Brain ischemia is considered to have three main etiologies: thrombosis, embolism or 
hypoperfusion.46 The common denominator for thrombosis and embolism in an 
arterial occlusion leading to focal ischemia in a region of the brain. In thrombosis, 
blood flow to a region of the brain is inhibited due to a local process causing 
obstruction within the vessel. In embolism, blood flow is inhibited due to a 
thromboembolic clot originating somewhere else in the circulation. In hypoperfusion, 
brain ischemia is caused by a reduction of cerebral perfusion pressure below a critical 
threshold, and ischemia usually develops first in the border zones between the major 
cerebral arteries.  
Determination of the etiology of the ischemic event is essential, as etiology impacts 
treatment and outcome after ischemic stroke.47 Hence, the three above described main 
etiologies are further divided into subtypes, as the risk of recurrence and outcomes 
differ based on the location and type of the ischemic process. In the case of 
thrombosis, there is a significant difference in risk of recurrence if the atherosclerotic 
process originates in a large (e.g. carotid) or a small (e.g. lenticulostriate) vessel. In 
the case of embolism, treatment is dependent on the origin of the emboli (e.g. heart or 
the venous system). These observations have led to development of different 
classification systems. The Trial of Org 10172 in Acute Stroke Treatment (TOAST), 
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which was used in the present study, is an etiological classification system originally 
developed for clinical trial standardization, but is now routinely applied in clinical 
practice.48 TOAST classifies stroke into five subtypes: large-artery atherosclerosis 
(LAA), cardio embolism (CE), small vessel occlusion (SVO), stroke of other 
determined etiology (SOE), or stroke of undetermined etiology (SUE). Classification 
of an ischemic stroke or TIA into one of these subtypes is based on a combination of 
clinical features and diagnostic tests such as brain imaging, cardiac examinations 
(echocardiogram, ultrasound, etc.), imaging of extra- and intracranial vessels, and 
laboratory tests.49 While TOAST may be the most adopted classification system, it 
has also been criticized because a high proportion of patients, in many studies up to 
40%, are classified into the unspecific “stroke of undetermined etiology” category.50, 
51 This is in part due to a nonhierarchical classification structure where strokes with 
several possible etiologies are grouped into SUE. In an attempt to improve precision, 
several other classification systems have been developed. The most frequently used 
are ASCO (A for atherosclerosis, S for small-vessel disease, C for cardiac source, and 
O for other cause), SSS-TOAST (Stop Stroke Study Trial of Org 10172 in acute 
stroke treatment), CCS (Causative Classification System) and CISS (Chinese 
ischemic stroke subclassification).52-55 They all differ in their reliability to classify 
strokes into subtypes, which makes comparison between them challenging.53, 56, 57 
Classification systems also suffer from inter-observer variability, which is especially 
evident in studies with small sample sizes.58 Although one study found that CCS had 
higher validity and generated better distinct subtypes compared with TOAST and 
ASCO,51 TOAST still seem to remain the most used system.  
 
TOAST subtypes 
Large-artery atherosclerosis (LAA): Atherosclerosis is a process originating in the 
tunica intima layer of arteries in regions of disturbed blood flow. The cause is 
dysfunction of the endothelial cells that triggers an inflammatory response and 
 
 
triggers retention of lipoproteins in the subendothelium.59 This process usually 
develops in sites where arteries branch, bifurcate or curve, due to high shear stress-
gradients (atheroprone flow).60 These depositions of lipids cause plaques, which may 
rupture and cause local obstructions of arteries, or releasing emboli causing distal 
occlusions. Large arteries include both the extracranial arteries (carotids and vertebral 
arteries) and proximal branches of the intracranial arteries, including the Circulus 
Willisi. LAA is one the most common stroke subtypes, causing about 10-30% of all 
strokes depending on the age and ethnicity of the population.61-70 There are also major 
geographical differences in prevalence of intracranial atherosclerotic disease (ICAD), 
which is especially prevalent in Asia.71 TOAST criteria require an intra- or 
extracranial stenosis of >50% to classify a stroke as LAA, a criterion originating from 
the NASCET study in which carotid stenoses were graded from angiograms.49 Since 
then growing evidence has shown that even in non-stenotic arteries, both intra- and 
extracranial, the presence of high-risk atherosclerotic plaques may cause ischemic 
stroke or TIA due to artery-to-artery embolization.72, 73 
Cardioembolism (CE): An emboli from the heart to the brain can result from three 
mechanisms: local hemostasis (e.g. ventricular aneurysm), release of material from an 
abnormal valvular surface, or paradoxical (venous) emboli.74 Essentially any heart 
condition can lead to formation of an embolus, but the most frequent cardiac 
condition associated with CE is atrial fibrillation (AF). Other causes of cardioembolic 
stroke are systolic heart failure, recent myocardial infarction, patent foramen ovale, 
aortic arch atheroma, prosthetic heart valves and infective endocarditis.75 CE causes 
in general more severe strokes than other subtypes with worse outcome and higher 
socio-economic costs.76-79 CE is responsible for about 20% of all ischemic strokes.80 
Small vessel occlusion (SVO): Cerebral small vessel disease (SVD) is a term used to 
describe different pathological processes affecting small arteries, arterioles, venules 
and capillaries of the brain.81 SVD shares some common characteristics with large 
artery disease, like endothelial dysfunction and inflammation, but has also its unique 
features due to different vascular structure and mechanics.82 The resulting vascular 
damage, termed arteriosclerosis, lipohyalinosis or fibrinoid necrosis, is characterized 
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by fibrin deposition and smooth muscle damage, resulting in a thickened and stiff 
vessel wall.83 These processes may lead to local vessel occlusion, although there are 
indications that distal embolization from other vessels may also occur.84 The resulting 
lesions are mainly located subcortically and are observed as lacunar infarcts, 
microbleeds, white matter intensities or even large hemorrhages. SVD is also an 
established cause of cognitive impairment, most likely due to disruption of functional 
networks in the brain.85, 86 The proportion of ischemic stroke caused by SVO ranges 
from 7-40% in different populations.66-70 
Stroke of other determined etiology (SOE): Beside cardiovascular disease, there are a 
large number of traumatic, immune-mediated, genetic, hematological, infectious, 
malign and other causes of stroke.80 One of the most common causes is dissection of 
extra- or intracranial arteries.87, 88 SOE is especially prevalent in young stroke 
patients, where it accounts for 20-30% of cases.89, 90 
Stroke of undetermined etiology (SUE): Often, and even with thorough evaluation, 
the etiology of a stroke is not found. Stroke etiology is classified as SUE when an 
apparent cause is lacking. This may occur either despite proper examinations, or 
when multiple competing etiologies are identified, or due to insufficient 
examinations, like with the concept of embolic stroke of undetermined cause 
(ESUS).48, 91 When stroke etiology is classified by TOAST, up to 50% of patients will 
end up with an undetermined or cryptogenic cause.50, 51 
 
Ischemic stroke risk factors  
There are many risk factors associated with ischemic stroke. As for other diseases, by 
nature, some are modifiable, and some are not. Non-modifiable risk factors are 
factors that influence the risk and etiology of stroke, but are not alterable. Example of 
such factors are age, sex, race/ethnicity and genes (currently).92 Modifiable risk 
 
 
factors are conditional on a patient’s environment and subject to change by will or 
treatment. Example of such factors are comorbidities and lifestyle choices (e.g. 
smoking, diet, alcohol consumption, amount of physical exercise). A study with 
26919 participants from 32 countries worldwide reported that 90% of stroke risk was 
attributed to ten modifiable risk factors: hypertension, current smoking, waist-to-hip-
ratio, diet, physical activity, diabetes mellitus, alcohol intake, psychosocial factors, 
cardiac disease and ApoB/ApoA1 ratio.93 
 
Age 
The incidence of stroke increases with age and affects mainly people aged 60 years 
and older.10 In a meta-analysis including studies worldwide, mean age for first stroke 
was 68.6 years for men and 72.9 for women.94 For the Norwegian population, the 
mean age for first stroke in 2017 was 72 years and 77 years for men and women 
respectively.95 As previously mentioned, a population-wide reduction in ischemic 
stroke incidence in industrialized countries has been observed over the last decades.8, 
9 This applies mainly to the elderly population (>54 years of age) as a significant 
increase in incidence has been observed in the young.96 It is unclear if this increase in 
young stroke is due to changes in risk factors among the younger population, or 
advances in stroke diagnostics driven by a substantially increased use of MRI.  
 
Sex 
A meta-analysis reported that males have a 33% higher stroke incidence rate than 
females, although females have a 41% higher prevalence of stroke.94 The latter is due 
to longer life expectancy in women.97 Some stroke risk factors are unique for females, 
such as different composition of sex hormones, estrogen intake and factors associated 
with pregnancy and the post-partum state.98 Because of these sex-specific factors, 





There are significant ethnic differences in stroke risk. The prevalence and burden of 
common stroke risk factors differ substantially between races.93, 100-104 For instance, 
blacks have in general more vascular risk factors than Caucasians and the proportion 
of intracranial atherosclerosis is higher in Asians.72, 104 Although some of the 
observed ethnic disparities may be ascribed to differences in health-care access, 
awareness about these differences is important in a world with considerable human 
migration.99   
 
Genetic factors 
The risk of ischemic stroke is influenced by hereditary factors. Both single genes and 
genome wide genetic variants have been associated with increased stroke risk.99, 105 A 
study that assessed heritability of ischemic stroke from genome wide association 
studies data (GWAS) found that heritability for all types of ischemic stroke was 
37.9%, but varied significantly between subtypes. The highest heritability was 
reported for LAA whilst the lowest was reported for SVO.106   
 
Hypertension 
Hypertension is a highly prevalent modifiable risk factor for ischemic stroke.82, 107, 108 
Hypertension is now defined as systolic BP ≥130 mm Hg and/or diastolic BP ≥80 
mm Hg.109 The risk of stroke is increasing with increasing blood pressure levels, also 
in patients with pre-hypertension (systolic BP 120-129 mm Hg).110, 111 Conversely, 
treating hypertension has a significant effect on stroke risk. A Norwegian study found 
that lowering of systolic blood pressure accounted for 26% of the observed 1.7% 
annual decline of ischemic stroke incidence in the Tromsø area.27 In 2017 in Norway, 





Elevated cholesterol is one of the major factors in the development of atherosclerosis 
and ultimately cardiovascular disease.10, 112 This is especially relevant to coronary 
heart disease where atherosclerosis is a key element.113 Stroke is a much more 
heterogeneous disease and the relationship between stroke and lipids is more 
complex. Elevated total cholesterol levels are associated with ischemic stroke of LAA 
and SVO subtypes.114 
 
Diabetes mellitus 
Hyperglycemia manifested as diabetes mellitus, as well as prediabetes, is a major and 
increasingly prevalent risk factor of ischemic stroke.115, 116 Diabetes doubles the total 
risk of having an ischemic stroke and is associated with poorer outcomes.115, 117. The 
duration of the disease is also significant. One study found that the risk of ischemic 
stroke increased 3% each year with diabetes.118 In some studies, the prevalence of 
prediabetes is as high as 50% in ischemic stroke patients.116 In Norway, the 
prevalence of known or concurrent diabetes among stroke patients was 18.2% in 
2017.95  
 
Atrial cardiopathy and atrial fibrillation 
Atrial fibrillation (AF) is in numerous studies persistently associated with increasing 
the risk of ischemic stroke. Cardioembolic ischemic stroke is increasing in high-
income countries due to higher life expectancy, increasing prevalence of AF and 
better control of risk factors leading to LAA and SVO strokes.119, 120 In a recent 
publication from the Oxford Vascular Study (OXVASC), one of three incident 
ischemic strokes were associated with AF.121 AF is considered to increase the risk of 
stroke 3-to 5-fold and affects at least 9% of all people aged 80 years and older.122, 123 
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Recent findings have questioned the long-lived assumption that AF is an essential 
thrombogenic component in Virchow’s triad and the direct cause of atrial blood stasis 
in thrombus formation.124, 125 In a study from Taiwan, AF did not increase the risk of 
stroke in men without other risk factors (CHA2DS2-VASc score = 0).126 In several 
studies, continuous heart rate monitoring detected AF only after incident stroke, 
despite monitoring several months prior to the stroke.127, 128 Other types of atrial 
disease (e.g. premature atrial contractions) without evidence of AF or other 
tachyarrhythmias have also been associated with increased risk of embolic stroke.99, 
129 This evidence has led to the concept of atrial cardiopathy, a term that also includes 




Smoking, both active and passive, is unfortunately still a major risk factor for stroke. 
Current smoking doubles the risk of stroke with a dose-dependent effect, as the risk 
increases with 12% for each increment of 5 cigarettes/day.131 Other life-style factors 
associated with increased risk of stroke are sedentary behavior, nutritional factors and 
obesity.99 While heavy alcohol consumption is a risk factor for ischemic stroke, 
moderate alcohol consumption (≤14 units/week for men and ≤7 for women) is 
thought to be protective.132 Recent studies have questioned this association 
demonstrating an increase in stroke risk even with light alcohol consumption.133  
 
Stroke triggers 
Observations of patterns in the onset of ischemic stroke in relation to different acute 
factors, has led to evolution of the concept of “stroke triggers”.134 These factors 
transiently increase the risk of stroke and may be related to other diseases, the 
environment or a patient’s behavior. Examples of such triggers of ischemic stroke are 
 
 
drug/alcohol abuse, infection/sepsis, stress, air pollution and changes in the ambient 
temperature.134-140 
 
Ischemic stroke prevention  
The goal of stroke prevention is reduction of stroke incidence by risk factor 
modification. High-quality prevention of ischemic stroke has the potential of 
reducing both the absolute number and the severity of strokes, with a reduction in 
suffering and costs involved in salvaging and rehabilitating established disease.108  In 
general, prevention may be achieved on three different levels; 1) primordial 
prevention, which is prevention of risk factor development on a group level;141 2) 
primary prevention, which is modification and improvement of risk factors of 
ischemic stroke on an individual level once present;142 and 3) secondary prevention, 




Primordial prevention is ultimately risk reduction through behavioral modification in 
a population, such as increase in physical activity, smoking cessation strategies and 
elimination of public passive smoking exposure, promotion of healthy diets, diet 
sodium reduction and diabetes screening.143 Clinical studies on the effects of a 
“polypill”, containing a fixed dose combination of blood pressure agents and a statin 
(with or without acetylsalicylic acid), in middle-aged individuals without 
cardiovascular disease, demonstrate potential for major risk reduction on a population 
level.144, 145 Such strategies may be especially attractive in countries where access to 





Addressing major risk factors for cardiovascular disease in an individual is the 
cornerstone of primary prevention. Intuitively estimating an individual’s risk of 
future cardiovascular events or death is difficult, because cardiovascular risk is 
conditional on many factors. Thus, several scoring systems have been developed for 
different populations, such as the Framingham Risk Score, SCORE, ASCVD Risk 
estimator + and NORRISK2.142, 146-148 These risk estimators typically calculate an 
individual’s 10-year risk of a cardiovascular event or death based on factors like age, 
sex, blood pressure levels, cholesterol levels, diabetes and smoking. Risk estimation 
is a valuable asset in order to determine the measures, timing and treatment goals of 
primary prevention in risk patients.142 A French study demonstrated that general 
practitioners intuitively rated the cardiovascular risk incorrectly in >70% of patients, 
rated as high-risk by the Framingham and SCORE systems.149  
 
Secondary prevention 
In patients with established ischemic stroke or TIA, the main intention of diagnostic 
evaluation is to initiate the most appropriate measures to reduce the risk of further 
strokes. Improved acute stroke treatment with higher rates of thrombolytic- and 
endovascular treatment, more independence and improved survival, indicates that an 
increased number of stroke survivors are susceptible to recurrent strokes.8, 29, 150-153 
Secondary prevention focuses on identification of stroke etiology, administration of 
proper preventive treatment (e.g. medications, carotid revascularization) and 
modification of cardiovascular risk factors (e.g. exercise, smoking cessation, dietary 
changes).  
Almost all ischemic stroke patients are treated with some type of antithrombotic 
therapy, either antiplatelet or anticoagulant therapy. Antiplatelet agents reduce the 
risk of recurrence in non-CE stroke patients by about 15%,154 while anticoagulants 
 
 
lower the ischemic stroke risk by about 60% in patients with atrial fibrillation.155 
Anticoagulants are recommended as secondary prevention therapy in most patients 
with CE-stroke156 and are in general not indicated in non-CE stroke due to their 
association with major hemorrhage, which outweighs their efficacy in preventing 
recurrence in other subtypes than CE.157 
In addition to antithrombotics, treatment of hypertension may be the most significant 
measure.156 About 60-70% of stroke patients have a history of, or present 
hypertension at the index event.158-161 Many large randomized controlled trials have 
demonstrated an association between blood pressure reduction and reduced risk of 
recurrent stroke. A recent meta-analysis of such studies found a 27% risk reduction of 
recurrent stroke with antihypertensive treatment, and this association was linear with 
decreasing levels of systolic and diastolic pressure.162 
Statin therapy is also a main component of non-CE secondary ischemic stroke 
prevention, although the association between cholesterol levels and ischemic stroke 
risk is more uncertain.156 Meta-analyses have demonstrated a 16% reduced risk of 
recurrent stroke of with statin therapy,163, 164 but there are indications that this effect is 
due to the anti-atherothrombotic effects of statins and not due to the reduction of 
blood cholesterol levels.165  
Optimal combination of secondary prevention therapies is necessary for maximum 
risk reduction of recurrence and death. In a multicenter study from Korea, optimal 
therapy reduced the risk of recurrent stroke with 60%, risk of major vascular events 
with 61% and all-cause mortality with 65%, compared with no secondary prevention 
therapy.26 In addition, a study reported that discontinuation of acetylsalicylic acid was 
associated with a 40% risk increase of recurrent ischemic stroke or TIA compared 
with continuation of therapy.166 The effects of different secondary prevention 





Recurrent ischemic stroke 
Recurrent ischemic stroke accounts for 25-30% of all strokes and increases morbidity 
and mortality in stroke patients.13, 15 The risk of recurrence is highest directly after 
incident ischemic stroke or TIA and declines over time.168 Many large incidence 
studies on recurrent stroke have excluded events occurring within the first month, 
meaning that data regarding early recurrence is limited and variable in quality.169 
Studies have reported recurrence risks of 1.6-15% at 30 days, 2.3-18% at 90 days, 
5.1-20.6% at 1 year and 16.2-38.7% at 5 years.15, 34, 36, 159-161, 168, 170-194 A meta-
analysis reported a cumulative risk of stroke recurrence of 3.1% at 30 days, 11.1% at 
1 year and 26.4% at 5 years.168  
The risk of ischemic stroke after TIA was previously considered to be high, 
especially the first few days. Several studies conducted around the year 2000 reported 
an ischemic stroke risk of around 10% the first month after clinical TIA, where up to 
half of recurrences happened during the first couple of days.195-197 Increasingly urgent 
management of TIA over the last decades have led to lower rates of ischemic stroke 
after TIA in recent studies, estimated to 2.8%, 5.1% and 9.5% at 30 days, 1 year and 
5 years respectively.174, 198  
The risk of undergoing a cerebral hemorrhage as the first recurrent event is low. 
Several studies have reported that in patients with ischemic stroke, the risk of the 
recurrent event being an intracerebral hemorrhage is about 5%.187, 199 This risk of 
intracerebral hemorrhage as recurrent event changes to 58% if the initial event was an 
intracerebral hemorrhage.199  
The association between risk of recurrent ischemic stroke and index stroke subtype is 
uncertain. This uncertainty is in part due to differences between studies regarding 
populations, etiology classification and statistical methods. Some studies found an 
association between risk of recurrence and subtype, reporting the highest association 
for large-vessel disease and cardioembolic stroke.185, 200-202 Other studies did not find 
 
 
any association between subtype and risk of recurrence.34, 68, 160, 203, 204 Stroke due to 
large artery atherosclerosis has been consistently associated both with early 
recurrence and with recurrence in younger patients.67, 161, 171, 200, 205, 206 
 
Recurrent stroke risk factors 
Many risk factors have been associated with recurrent stroke, even though there is a 
lack of consistency across studies. While recurrent ischemic stroke also is strongly 
associated with the major cardiovascular risk factors, no single factor has been 
consistently associated with recurrent ischemic stroke or TIA.207 Hypertension, level 
of education, prior stroke, diabetes, coronary heart disease, silent brain infarction, 
alcohol abuse, persistent smoking, discontinuation of aspirin, atrial fibrillation and 
the total burden of risk factors have all been reported as significant risk factors for 
recurrent stroke in different studies.160, 166, 173, 186, 194, 202, 203, 207-217 
 
Recurrent ischemic stroke and mortality 
Few studies have assessed the effect of recurrent ischemic stroke on mortality. A 
study from The Northern Manhattan Stroke Study did not find any difference in 
mortality between ischemic stroke patients with and without prior stroke.194 Another 
study on 50.000 Medicare patients reported that patients with recurrent stroke had 
poorer 2-year survival compared to patients with first stroke.182 Other studies have 
reported estimates ranging from a two-fold to a 17-fold increase in mortality after 
recurrence.15, 217-219 In these studies, recurrence has in general been the strongest 
factor associated with mortality. 
 
Stroke mimics after incident stroke 
Acute neurological symptoms may be non-specific or caused by other diseases than 
stroke. Consequently, many patients with suspected stroke turn out to have other 
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conditions, which are labeled as stroke mimics. A stroke mimic is usually defined as 
a condition not resulting from cerebral ischemia, but still presenting itself with 
neurological symptoms indistinguishable from stroke.220 Conditions like infections, 
migraine, seizures, syncope, vertigo, confusional states and functional symptoms are 
frequent stroke mimics.221-224 Stroke mimics lead to costly hospital admissions and 
are stressful for the patients and their family.225 Recognition of stroke mimics is 
therefore highly important, especially in an era with constant focus on shortening the 
time from hospital admission to administration of thrombolysis (door-to-needle time). 
While stroke mimics in patients without prior stroke have been subject of numerous 
studies,220-223, 226, 227 the phenomenon of stroke mimics is unexplored in patients with 
prior stroke. A brain already impaired from stroke is more likely affected by altered 
metabolic processes due to infections, seizures or other diseases, which may cause 
post-stroke recrudescence (PSR) of prior deficits.228 A recent study from the U.S. 
demonstrated that a history of prior stroke increased the risk of misdiagnosing a 
recurrent stroke more than two-fold.229 Thus, information about incidence and types 




Aims of the thesis 
1. To assess short- and long-term incidence of recurrence after index ischemic 
stroke or TIA (Paper I and II). 
2. To determine the etiologies of short-term recurrence (Paper I). 
3. To assess factors associated with short- and long-term recurrence after 
ischemic stroke or TIA (Paper I and II). 
4. To assess the incidence of all-cause mortality after index ischemic stroke or 
TIA (Paper II). 
5. To assess the impact of recurrence on all-cause mortality after index ischemic 
stroke or TIA. (Paper II) 
6. To assess the cumulative incidence of stroke mimics after index ischemic 
stroke or TIA and compare it to the incidence of recurrent ischemic stroke or 
TIA in the same time-period within the same population. (Paper III) 
7. To assess etiologies of stroke mimics after index ischemic stroke or TIA and 
investigate if these etiologies varies in frequency based on elapsed time after 






Materials and methods 
This thesis investigates recurrent events in a hospital‐based prospective cohort from 
the Stroke Unit at the Department of Neurology, Haukeland University Hospital, 
Bergen, Norway. All papers in the present thesis are based on index admission patient 
data from the NOR-STROKE registry, with subsequent follow-up data acquisition 
from the included patient’s electronic medical journals. The thesis is based on 
patients registered in the NOR-STROKE registry with index ischemic stroke or TIA 
between June 2007 and December 2013. Patients were followed for recurrent events 
from discharge and until September 1, 2016. Follow-up data collection was 
performed mainly during 2017. 
The study population is identical in all papers. During the inclusion period, 1988 
patients were diagnosed with ischemic stroke or TIA in the Stroke Unit, of whom 116 
died during the index admission or were discharged to palliative care (5.8%). The 
final cohort consisted of 1872 patients with index ischemic stroke (n = 1666) or TIA 
(n = 206). In paper I, the studied cohort consisted of 1874 patients. During data 
analysis for paper II and III, two patients were found to be misclassified in the NOR-
STROKE registry as they had ICH as the index event. This was probably due to a 
registry plotting error and these patients were excluded from the analyses in paper II 
and III.  
 
Data from the index stroke admission 
The NOR-STROKE registry is an ongoing, prospective hospital-based registry that 
has included stroke patients admitted to the stroke unit at Haukeland University 
Hospital since 2006. The registry is a medical quality registry and is approved by the 
regional ethics committee and The Norwegian Data Protection Authority. 
Approximately 275 000 people are living in the area served by this stroke unit. The 
 
 
stroke unit is the primary unit for all stroke patients geographically affiliated with 
Haukeland University Hospital, as well as stroke patients <60 years of age that are 
affiliated with a neighboring hospital (Haraldsplass). For this thesis, only patients that 
lived inside this area at the time of the index ischemic stroke or TIA and were 
geographically affiliated with the Haukeland University Hospital stroke unit were 
included. Patients who moved outside of the defined geographic area before the end 
of data collection, and patients that died during index admission or were discharged 
to palliative care, were excluded from the study. Patients geographically affiliated 
with Haukeland University Hospital Stroke Unit, but admitted to other hospitals with 
index stroke, were also excluded from this study. 
Admission of patients with suspected stroke to Haukeland University Hospital 
happened either through primary care physicians (general practice or out-of-hours 
services), or directly to the hospital through the “code stroke” pathway, defined by 
the emergency medical dispatch protocol as suspected stroke with symptom onset <6 
hours. The National Institute of Health Stroke Scale (NIHSS) score was registered at 
admission. Computed tomography (CT) was performed in all patients without wake-
up stroke to exclude intracranial hemorrhages, assess early ischemic changes, or other 
symptomatic pathologies. In order to detect occlusions accessible to endovascular 
treatment, CT angiography was performed in patients with symptom duration <6 
hours. Patients with wake-up stroke were assessed with MRI DWI upon availability. 
The use of CT angiography, wake-up MRI and MRI in TIA patients evolved during 
the inclusion period. Thrombectomy was available as an experimental procedure 
from 2008, with an increasing number of thrombectomies over following years. 
Routine examinations of stroke patients in the stroke unit included brain imaging with 
MRI, duplex carotid ultrasound, ECG, 24‐hour minimum electrocardiographic 
monitoring, echocardiography if indicated and laboratory analyses. MRI was 
performed at index in a total of 87% (1629/1872) of patients in the cohort: in 88% 
(1465/1666) of patients with ischemic stroke and in 80% (164/206) of patients with 
TIA. Indications for assessment of dysphagia, apraxia and cognitive function by a 
speech therapist or occupational therapist were liberal.   
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The treating stroke neurologist administered NOR-STROKE registry inclusion during 
admission. Registration of data was conducted by use of a standardized form, which 
was filled in by the neurologist during stroke admission. The form included basic 
patient and clinical data like date and time of symptom onset, duration of symptoms, 
all registered NIHSS scores, functional scores and status, vital parameters, imaging 
data, results of diagnostic test, complications, prior medial history, cardiovascular 
risk factors, medications at admission/discharge and discharge status and destination. 
The patient was interviewed about the specific parameters during the index 
admission. Presence of comorbidities like hypertension, previous ischemic stroke or 
TIA or other cardiovascular disease were based on information from direct 
questioning, on existing hospital medical records, or if the patient were already on 
medications for specific conditions upon admission. In addition to the self-reported 
information from the patient, data from complementary sources like family (spouse, 
children, and other relatives) were also gathered when necessary. The current version 
of the pages in mention from the NORSTROKE form is included in the Appendix.  
Hypertension was defined as a history of treated hypertension or if the patient were 
using antihypertensive medications for hypertension upon index admission. Diabetes 
mellitus was defined as use of antidiabetic medication upon index admission. 
Hypercholesterolemia was defined as the use of lipid-lowering drugs upon index 
admission. Peripheral artery disease (PAD) was defined as a history of diagnosed 
peripheral artery disease prior to index admission.   
Prior ischemic stroke or TIA were defined as a history of a clinical episode of 
ischemic stroke or TIA reported by the patient or based on available medical journal 
information at index admission.  
Written informed consent to participate in the registry was obtained during admission 





Follow up data was obtained by accessing electronical hospital medical records. 
Recurrent events after index discharge were identified by identification of all new 
acute hospital admissions in the study period by looking up electronic medical 
records from all ten hospitals in the region administered by the Western Norway 
Regional Health Authority. The included hospitals are Haukeland University 
Hospital, Haraldsplass Deaconess Hospital, Voss Hospital, Stord Hospital, Odda 
Hospital, Haugesund Hospital, Førde Central Hospital, Nordfjord Hospital, Lærdal 
Hospital and Stavanger University Hospital. The region is one of four regional health 
authorities in Norway including approx. 1.1 million inhabitants in Western Norway.  
Every Norwegian citizen has a unique 11-digit national identity number which is 
given for life. This number is used for most administrative purposes, such as hospital 
admissions. All hospital records in Western Norway dating back several decades are 
electronic and are easily accessed for these patients with the national identity number.  
Data collected for each acute new admission included the dates for admission and 
discharge, primary and secondary admission departments, primary and secondary 
diagnosis (ICD-10, International Classification of Diseases, Tenth Revision), vital 
parameters, current smoking, if the admission was due to suspected stroke and also 
discharge destination. All new acute admissions with a diagnosis of ischemic stroke, 
TIA or stroke mimics were used for the analyses. For identification of stroke mimics, 
we tagged all acute admissions where the admission report diagnosis was suspected 
stroke, but the primary discharge diagnosis was other than ischemic or hemorrhagic 
stroke, or TIA. Suspected stroke was defined as a diagnosis of possible stroke in the 
admission report, or stroke investigation in patients admitted through the “code 
stroke” pathway where suspected stroke was the dispatch diagnosis by the emergency 
medical dispatch protocol.230 Current prescribed medications for each patient were 
registered at the first and last admission after index discharge. The primary ICD-10 
discharge diagnosis was registered. Stroke mimic was defined as any ICD-10 
discharge diagnosis other than intra-axial cerebral hemorrhage (ICH) (I61), ischemic 
40 
 
stroke (I63) or TIA (G45, excluding transient global amnesia G45.4). Cases with 
extra-axial hematomas, traumatic ICH and ICH related to neoplasia or thrombolytic 
treatment were excluded from the analysis.  
Information on death was collected electronically from the Norwegian National 
Registry through the medical electronic records system, DIPS, which is used by all 
ten hospitals administered by the Western Norway Regional Health Authority. Date 
of death were registered during the data collection phase in 2017. Elective admissions 
were not included in the present study.  
The collected data was categorized in a standardized form, created and stored in a 
data entry and documentation computer program (EpiData 3.1, Odense, Denmark).231  
For all papers included in the thesis, definition of recurrent ischemic stroke or TIA 
was the same as for the index stroke event, as described previously. Intracerebral 
hemorrhage or subarachnoid hemorrhage were not included as recurrent 
cerebrovascular events, as these conditions differ in pathology and are often 
associated with preventive medications prescribed after ischemic stroke or TIA.  
In paper I, the aim was to assess the etiologies of recurrent stroke the first 30 days 
after the index event. A secondary review of electronic medical charts focused on 
revision of the etiological evaluation, review of supplemental clinical and imaging 
data, with emphasis on intracranial pathology. Two doctors with experience in stroke 
medicine (ANK and HN) performed this review. A common cause for both episodes 
was reviewed and determined if possible.  
In paper II, the aim was to estimate the long-term cumulative incidence of recurrent 
ischemic stroke or TIA. We also determined the factors associated with long-term 
recurrence and how recurrent stroke influenced the all-cause mortality.  
In paper III, the aim was to estimate the long-term cumulative incidence of stroke 
mimics after incident ischemic stroke or TIA and compare it to the cumulative 
 
 
incidence of recurrent ischemic stroke or TIA within the same population in the same 
time period. Only admissions where clinical testing and observation in a stroke unit 
for possible stroke was initiated after initial emergency room evaluation were 




Univariate analyses were performed using the chi-squared test for categorical 
variables, and Students’ t-test for continuous variables. Wilcoxon rank-sum test was 
used for skewed continuous variables.  
Backward stepwise Cox regression was used for the multivariate analyses by 
inclusion of variables that turned out significant (P<0.05) in the univariate analyses. 
All models included age, sex, and functional scores (mRS/NIHSS) from index 
admission for confounding adjustment. 
Cumulative incidence of recurrence and stroke mimics was calculated with the 
cumulative incidence function (CIF) in a Cox model after applying the method of 
Fine and Gray by treating death as a competing risk.232 The Kaplan-Meier method 
was used to estimate the incidence of all-cause mortality.  
A Cox regression model with recurrence as a time-dependent covariate was 
constructed to assess the effect of recurrence on all-cause mortality in paper II. 
Known factors associated with mortality such as age, smoking, stroke severity and 
cardiovascular risk factors for stroke were included in the model.  
Visual inspection of the proportionality hazards-assumption showed no violation of 
proportionality in the models. 
In assessment of incidence rates, we accounted for the fact that some patients had 
several events of recurrent ischemic stroke or TIA (paper II) or stroke mimics (paper 
III) by creating an Andersen-Gill regression model.233 This model, which is an 
extension of the Cox model, is a method for analyzing data with repeated events. This 
is in contrast to the regular Cox model, which censors observations after occurrence 
of an event in question. The incidence rates per 1000 years with Poisson confidence 




Analyses were performed by use of Stata/SE 15.1 (Stata Corp LLC, LP, TX). 
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Summary of results  
Paper I: Thirty-day recurrence after ischemic stroke or TIA 
We identified 1874 patients who were discharged alive from our stroke unit after 
their index ischemic stroke or TIA during the inclusion period. A total of 33 patients, 
28 with ischemic stroke and five with TIA, (1.8%) were readmitted within 30 days 
after index stroke onset. By using TOAST, 12 patients were initially classified with 
stroke of unknown etiology (SUE). Etiologies behind recurrent ischemic stroke or 
TIA were after review of the recurrent episode identified as extracranial large artery 
atherosclerosis (LAA) in 14 patients (42.4%), intracranial arterial pathology in seven 
patients (21.2%), stroke of other etiology (SOE) in six patients (18.2%) (particularly 
active malignancy), and Cardioembolism (CE) in four patients (12.1%). Small vessel 
occlusion (SVO) and SUE were the causes in one patient each. Logistic regression 
showed that patients with stroke of other determined etiology (SOE) and LAA had 
increased risk of 30‐day recurrence (OR = 9.72, 95% CI 1.84–51.3, p < 0.01 and OR 
= 4.36, 95% CI 2.01–9.47, p < 0.01, respectively).  
Patients with LAA and SOE had increased risk of recurrent ischemic stroke or TIA 
within 30 days.  
 
Paper II: Recurrent ischemic stroke: Incidence, predictors, and 
impact on mortality 
We identified 1872 patients who were discharged alive from our stroke unit after 
their index ischemic stroke or TIA during the inclusion period. During follow‐up, 220 
patients had 277 recurrent ischemic strokes or TIAs. The cumulative recurrence rate 
was 5.4% at 1 year, 11.3% at 5 years, and 14.2% at the end of follow-up. 
Hypertension (HR = 1.65, 95% CI 1.21‐2.25), prior symptomatic stroke (HR = 1.63, 
 
 
95% CI 1.18‐2.24), chronic infarcts on MRI (HR = 1.48, 95% CI 1.10‐1.99), and age 
(HR 1.02/year, 95% CI 1.00‐1.03) were independently associated with recurrence. A 
total of 668 (35.7%) patients died during follow‐up. Recurrence significantly 
increased the all‐cause mortality (HR = 2.55, 95% CI 2.04‐3.18).  
The risk of recurrent ischemic stroke or TIA was modest in our population and was 
associated with previously established risk factors. Recurrence more than doubled the 
all‐cause mortality. 
 
Paper III: Incidence and etiologies of stroke mimics after 
incident stroke or TIA 
We identified 1872 patients who were discharged alive from our stroke unit after 
their index ischemic stroke or TIA during the inclusion period. During 8172 person-
years of follow-up, 339 patients had 480 stroke mimic events. The cumulative 
incidence rate of stroke mimics during follow-up was 58.7 per 1.000 person-years 
(95% CI 53.7-64.2), compared with 34.0 per 1.000 person-years (95% CI 30.2-38.2) 
for recurrent stroke in the same time-period. As for recurrent stroke, the risk of stroke 
mimics was highest the first year after index ischemic stroke or TIA. The most 
frequent diagnoses were sequelae of cerebral infarction (19.8%), medical observation 
and evaluation for suspected cerebrovascular disease (15.6%) and infections (14.0%). 
The two most frequent and non-specific diagnoses (sequelae of cerebral infarction 
and medical observation etc.) were clustered in the first months after index stroke.  
Stroke mimics after initial ischemic stroke are more frequent than recurrent stroke 
and the risk is especially high in the early period after stroke. Stroke mimics are 
multi-etiological in nature and non-specific diagnoses are most frequent directly after 




Early recurrent ischemic stroke or TIA 
The incidence rate of 30-day recurrence of ischemic stroke or TIA in our hospital-
based cohort was 1.8%. There is scant information on early or late stroke recurrence 
in Norway, but our rate is among the lowest recurrence rates compared to previous 
studies that reported incidence rates between 1.6-15%.15, 76, 159-161, 174, 179, 184, 185, 189-191, 
193, 194, 200, 234-236 Comparability of results is limited in these studies due to differences 
in methodology, follow-up and populations. Table 1 demonstrates the 30-day 











Type of follow-up 
 
 
Sacco, 1989* 3.3 Stroke Data Bank Follow-up at 3 months 
Sacco, 1994* 6.0 NOMAS Follow-up at 6 months/telephone 
Lauria, 1995 1.9 Community-based Readmissions/Referral via GP  
Lin, 1996* 4.7 Framingham Follow-up at 3 months 
Rundek, 1998* 2.9 NOMAS Follow-up 
Petty, 1998* 4.4 Population study Medical records review 
Moroney, 1998* 4.4 Single stroke unit Follow-up/interview at 90 days 
Hardie, 2004 2.0 PCSS Follow-up/interview 
Modrego, 2004 2.1 Single stroke unit Readmissions 
Lovett, 2004* 4.2 OXVASC Follow-up at 1 month 
Coull, 2004 15.0 OXVASC Referral via GP 
Smith, 2005 4.2 Administrative Readmissions, administrative data 
Dhamoon, 2006* 1.5 NOMAS Follow-up at 6 months 
Bravata, 2007* 1.6 Administrative Readmissions, administrative data 
Xu, 2007* 5.5 Stroke Registry data Follow-up at 2-3 months 
Mohan, 2009 1.1 Stroke Registry data Follow-up at 3 months 
Burke, 2014* 5.0 Administrative Readmissions, administrative data 
Amarenco, 2016* 2.8 TIAregistry.org Follow-up at 1 month 
     
* Denotes studies on ischemic stroke only. Abbreviations: NOMAS, Northern 
Manhattan Stroke Study; PCSS, Perth Community Stroke Study; OXVASC, Oxford 
Vascular Study and the Oxfordshire Community Stroke Project; 
 
Most of these studies report a 30-day recurrence rates in the 1.5-5% range. Eight of 
the listed studies in the table are included in the previously mentioned meta-analysis 
by Mohan et. al. from 2011 that reported a pooled 30-day recurrence incidence rate of 
3.1%.168 Only two of the studies listed in the table was published in this decade. Lack 
of recent studies makes the impact of contemporary changes in risk factors and 
secondary prevention strategies on 30-day recurrence difficult to assess.     
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The wide variations in incidence between studies may be explained by differences in 
methodology and definitions of recurrent stroke. Most studies listed in the table were 
prospective with regular follow-up appointments where the possibility of recurrence 
was considered. The most widespread definition of recurrence were all of, or a 
combination of the following characteristics: neurologic deficit of vascular origin 
lasting at least 24 hours; located in a different vascular territory; or being of a 
different subtype.15, 161, 184, 185, 194, 200, 234 Some studies excluded events during the first 
21 days.160, 184 Some studies only included minor stroke or TIA.174, 189 The use of CT 
and or MRI were also variable across studies. The most recent study, by Amarenco 
et. al, defined recurrence also as a symptomatic deterioration of previous neurologic 
deficits accompanied by neuroimaging evidence of new brain infarction. This is a 
sensible approach, considering that a cerebral infarction is a dynamic process that 
may evolve during the first days/weeks. A study that investigated new ischemic 
lesions in patients with minor stroke or TIA with a follow-up MRI done 30 days after 
initial ischemic stroke or TIA, found that the majority of symptomatic events were 
rated as progression of the original infarct and that events outside of the initial 
vascular territory were rare.237  
Of the listed studies, 6/18 included also patients with hemorrhagic stroke at index. 
Hemorrhagic stroke constitutes 10-15% of all stroke, which implies that most patients 
in these studies had ischemic etiology. The meta-analysis by Mohan et al. included 
studies with all stroke types and found no differences in recurrence rates at 1 year 
between studies reporting recurrence after ischemic stroke only, compared with 
studies also including hemorrhages. Differences in incidence of recurrence rates 
between ischemic stroke and ICH were not assessed at earlier time-points like 30 
days. If the early recurrence rate of hemorrhagic stroke differs significantly from 
ischemic, it may have influenced the reported 30-day recurrence rate in these studies. 
In addition, since hemorrhagic stroke has higher early mortality than ischemic stroke, 
a selection bias may also be present. Unfortunately, even less is known about early 
recurrence of hemorrhagic stroke than ischemic. A meta-analysis reported an annual 
 
 
risk of recurrence after spontaneous ICH between 1.3-7.4%, but most of these studies 
started follow-up at 30 or 90 days after the hemorrhage.238 One recent study 
investigating recurrence up to 5 years after primary ICH reported the cumulative 
recurrence risk of ICH after 28 days being 3.67% (95% CI 3.37-3.97),239 which is 
comparable to many ischemic stroke studies.  
Two studies reported 30-day recurrence after minor stroke or TIA (mRS 0/1 or 
NIHSS <4). About half of our study population had these characteristics. These two 
studied reported discrepant 30-day recurrence rates. The study by Coull et al. reported 
the highest rate by far with a 15% risk of 30-day recurrence.189 This study from the 
early 2000s on 174 patients (87 minor stroke and 87 TIAs) included patients in an era 
where guidelines recommending that TIA patients should be assessed within two 
weeks.  In fact, several patients suffered recurrence before they were even seen by a 
physician. The most recent study on 4789 patients, by Amarenco et al., where 
patients were assessed within hours or next day, reported a recurrence rate of 2.8%, 
which is more in line with other results.189  
 
Factors associated with early recurrent stroke 
In our study, patients with large-artery atherosclerosis had the highest risk of 30-day 
recurrence. This is in line with results from other studies reporting 30-day recurrence 
stratified by stroke subtype. Sacco et al. reported that patients with atherosclerosis 
had a 30-day recurrence risk of 8% in one study, and 14% in another.194, 234 Lacunar 
stroke had the lowest risk of early recurrence in these studies. Moroney et al. reported 
that atherothrombotic stroke mechanism had a RR of 3.3 (95% CI 1.3-8.3), which 
was higher than for atrial fibrillation.200 Modrego et. al reported the highest 30-day 
risk of recurrence for cardioembolic stroke at 3.5%, higher than for atherothrombotic 
at 2%.185 In the most recent study, Amarenco et al. found that large-artery 
atherosclerosis is a stroke subtype that is associated with a significantly higher risk of 
recurrence compared with other etiologic stroke subtypes.174 In a study including only 
patients with LAA, with symptomatic carotid stenosis, Strömberg et al reported a 30-
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day recurrence of 7.5%, higher than most estimates on general stroke populations.240 
Rapid carotid endarterectomy (CEA) is highly effective for reducing recurrent stroke 
in selected patients with stenosis of the internal carotid artery.241 The possible 
consequences may be demonstrated in paper I, as four of five patients found eligible 
for CEA, suffered a recurrent stroke within 30 days before surgery.  
In paper I, we demonstrated that a significant part of patients with recurrence had 
intracranial artery stenosis (ICAS). ICAS has a high risk of recurrent stroke in the 
same vascular territory.242 Ovesen et al. reported a higher risk of recurrence in stroke 
patients if intracranial atherosclerosis were detected during acute evaluation for 
stroke.243 In a sub-analysis of the “Prospective study of symptomatic 
atherothrombotic intracranial stenosis” (GESICA), Mazighi et al. reported a 2-year 
risk of recurrent stroke in the territory of an symptomatic intracranial stenotic artery 
to be 38% despite medical therapy, which is much higher than for ischemic stroke in 
general.244 Still, the risk of early recurrence in patients with ICAS is poorly studied. 
In a sub-study of the “The Warfarin-Aspirin Symptomatic Intracranial Disease” 
(WASID) study, Ovbiagele et al. found a 30-day risk of ischemic stroke in the arterial 
territory of the symptomatic stenotic intracranial artery to be between 3-9.5%, 
depending on the type of index event (TIA, ischemic stroke or both).245 In a study on 
patients with clinical TIA attributable to intracranial artery disease, but with lesions 
on DWI, the 90-day recurrence risk was 14.6%, with most patients experiencing 
recurrence during the first week.246 Recognition of ICAS as the cause of ischemic 
stroke or TIA is important, as proper rapid medical treatment and risk factor control 
(e.g. blood pressure reduction) may reduce the risk of early recurrence.247, 248   
Among factors associated with early recurrence, peripheral artery disease (PAD) was 
a predictor of early recurrence in the multivariate analysis in paper I. PAD is a 
common type of atherosclerosis that affects peripheral arteries. Presence of PAD, or 
low ankle-brachial index which is a measure of arterial stenosis in the lower 
extremities, is associated with increased risk of recurrent stroke.249 A meta-analysis 
by Hong et al. demonstrated that the pooled hazard ratio for recurrent stroke in 
 
 
patients with PAD was 1.70 (95% CI 1.1-2.6) compared with patients without PAD. 
One study by Tsivgoulis et al. that investigated the association between PAD and 
early ischemic stroke recurrence, demonstrated that patients with low ankle-brachial 
index had much higher cumulative 30-day recurrence rate (19.2%; 95%CI: 4.1–34.3) 
compared to the rest (3.3%; 95%CI: 0.4–6.2%; p = 0.001).250  In total, atherosclerosis 
either as large-artery disease or intracranial disease, was found to be responsible for 
21/33 (64%) of recurrent strokes in paper I. PAD is another manifestation of 
atherosclerosis and was present in 21% of patients with 30-day recurrence. It is 
therefore not surprising that there was an association between PAD and recurrence in 
the multivariate analysis.  
In the multivariate analysis in paper I, stroke of other etiology was significant 
predictor of 30-day recurrence. This was due to a significant number of patients 
(6/33, 18%) with recurrence having cancer as the suspected underlying cause of both 
the index and recurrent strokes. With an aging population, cancer incidence is rising 
resulting in an increasing proportion of patients susceptible to cancer associated 
stroke. On autopsy, 15 % of cancer patients have evidence of cerebrovascular 
disease.251 Twenty percent of all deep vein thrombosis (DVT) and pulmonary 
embolisms are diagnosed in cancer patients.252 Although there is no consensus on 
diagnosis of cancer-related hypercoagulability, these patients often have migratory 
thrombosis, high D-dimer levels, and multiple arterial or venous events in several 
vascular territories.252, 253 Cancer of lung, pancreas and gastrointestinal tract are the 
most common causes of cancer-related hypercoagulability.252 In paper I, of the six 
cases recurring the first 30 days due to cancer-related stroke, three patients had 
pulmonary cancer, two pancreatic, and one thyroid. Only one patient was recognized 
as having cancer-related stroke and classified as SOE at index event. Three were 
classified as CE and two as SUE. In 5 of 6 patients, a primary tumor was identified 
by CT, in the last one, a thyroid tumor was diagnosed with a PET scan. Of six 
patients diagnosed with cancer related stroke and recurrence, five had multiple 
infarctions and clinical symptoms from several vascular territories, three patients 
presented with DVT and/or PE during index or second admission and all had elevated 
D-dimer levels on index stroke admission, half of which above the upper detection 
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threshold of 20 mg/L. In clinical practice, patients with cancer associated stroke are 
known to be prone to recurrence, but only a few reports about recurring stroke in 
cancer patients exist. In a study from 1994, 2 of 33 cancer patients suffered recurrent 
stroke during an average follow-up of >9 months.254 In a more recent study, the 
authors reported 36 recurrent ischemic strokes in 263 patients with a median survival 
of 84 days.255 With proper etiological investigation and focus on other signs and 
symptoms of hypercoagulability (e.g. migratory thrombosis, high D-dimer levels), 
stroke recurrence might be prevented by early diagnosis of cancer and administration 
of anticoagulation. 
In paper I, after re-evaluation, we found a common subtype for index and recurrent 
stroke in all but one patient. Recurrent stroke seem to be predominantly of the same 
subtype as the first or index stroke, although few studies have explored this matter.187, 
199, 201, 256 Especially cardioembolic stroke demonstrate a tendency to recur as the 
same type, reported in 77-94% of cases in some studies.187, 199, 201 Small-vessel 
occlusion or lacunar infarction seem to have the lowest risk to recur as the same 
subtype.187, 199, 201, 256 No studies seems to have explored the correlation of subtypes of 
early recurrence. Assuming that recurrent ischemic stroke or TIA within 30 days 
would be caused by the same pathological process in most cases, we investigated if 
the TOAST classification system could accurately determine the etiological subtype 
already at index stroke.  
Table 2 demonstrates the differences in etiologies classified by TOAST between the 




Table 2. Differences in TOAST etiology classification between index and 
recurrent event.  
Etiology (TOAST) 
   Atherosclerosis (LAA) 
   Cardioembolism (CE) 
   Small vessel disease (SVO) 
   Other determined (SOE) 
   Undetermined (SUE) 













In our data, by classifying etiology with TOAST, stroke due to LAA was 
underclassified as cause at index and many patients with LAA were classified in the 
SUE group, despite demonstrating pathology of extra- or intracranial arteries. Adams 
et al. formulated the following in their original publication on TOAST; “The 
diagnosis of stroke secondary to large-artery atherosclerosis cannot be made if 
duplex or arteriographic studies are normal or show only minimal changes.”48 By 
using nothing but the grade of stenosis (> 50%) as the foundation of LAA-
classification, newer insights into the pathophysiology of atherosclerosis and plaques 
are overlooked. Improvements in imaging techniques such as high-resolution MRI 
angiography, contrast-enhanced ultrasonography and PET/CT have evolved the 
concept of plaque vulnerability.73 Presence of plaque characteristics such as 
ulceration, intraplaque hemorrhage, slim cap thickness and a lipid-rich necrotic core 
are associated with an increased risk of plaque rupture even in non-stenotic arteries.72, 
73, 257  
TOAST is primarily a research tool. In clinical practice, the stroke neurologist should 
properly evaluate even minor atherosclerotic intra- or extracranial pathology in order 
to determine the correct secondary prevention treatment in each case. Still, our results 
demonstrate that stroke patients without “significantly” stenotic atherosclerotic 
disease or malignancies are at high risk of early recurrence. Classifying such cases in 




Long-term recurrent ischemic stroke or TIA 
In paper II, we reported the long-term recurrence rates of recurrent stroke. The 
cumulative incidence of first recurrence by years after index stroke in our stroke unit 
are demonstrated in table 3.  
Table 3. Cumulative incidences of first recurrent ischemic stroke or TIA by 
years after index stroke from the NOR-STROKE registry 













The cumulative incidence of first recurrent ischemic stroke or TIA was highest the 
first year after index ischemic stroke or TIA, and the rate of recurrence stabilized 
after about 4 years. At the end of follow-up, the risk of having at least one recurrent 
ischemic stroke or TIA was 14.2%.  
Table 4 demonstrates 5-year recurrence rates reported in other studies.15, 160, 172, 173, 176, 












Type of follow-up 
 
 
Sacco, 1982 42/24 Framingham Regular follow-up 
Meissner, 1988 19.3 Rochester Regular follow-up 
Viitanen, 1988 37 Population-based Regular follow-up? 
Burn, 1994 30 OXVASC Regular follow-up 
Sacco, 1994* 25 NOMAS Regular follow-up 
Hankey, 1998 22.5 PCSS Regular follow-up 
Petty, 1998* 39.3 Rochester Regular follow-up 
Eriksson, 2001 38.7 Single stroke-unit Regular follow-up 
Modrego, 2004 26.0 Single stroke-unit Readmissions 
Hata, 2005 51.3 Population-based Regular follow-up 
Dhamoon, 2006* 18.3 NOMAS Regular follow-up 
Mohan, 2009 16.2 Stroke Registry data Regular follow-up 
Lewsey, 2010 10.8 Country-wide Readmissions, administrative data 
Sun, 2013 18.4 Multi stroke-units Readmissions, administrative codes 
Pennlert, 2014 18 WHO MONICA Regular follow-up 
Li, 2015* 20 OXVASC Regular follow-up 
Edwards, 2017 7.8 Single stroke-unit Readmissions, administrative data  
Amarenco, 2018* 9.5 TIAregistry.org Regular follow-up 
Salehi, 2018 14.5 Stroke Registry data Regular follow-up? 
Zhao, 2019 26.3 Population based Regular follow-up 
* Denotes studies on ischemic stroke only. Abbreviations: OXVASC, Oxford 
Vascular Study and the Oxfordshire Community Stroke Project; NOMAS, Northern 
Manhattan Stroke Study; PCSS, Perth Community Stroke Study; 
WHO MONICA (Multinational Monitoring of Determinants and Trends in 
Cardiovascular Disease) Project;  
Compared with studies on early recurrence where only 6/18 of the examined studies 
included patients with hemorrhagic stroke at index and/or recurrence, 15/21 studies 
reporting 5-year recurrence rates included hemorrhagic stroke at index and/or follow-
up. Five of the studies mentioned in the table were included in the meta-analysis by 
Mohan et al. that reported a cumulative 5-year recurrence risk of 26.4%.168 
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As for early recurrence, differences in study populations, follow-up, definitions of 
recurrence and inclusion of hemorrhagic stroke may explain some of the observed 
differences between studies.  
The more recent studies demonstrated in table 4 show in general lower incidences of 
recurrence, except studies from Asian populations. Still, studies on stroke recurrence 
trends differ on whether recurrence rates are declining in industrialized countries.168, 
265, 266 Some studies from selected populations indicate a decline in recurrence 
rates,175, 267-269 other have reported an increase in incidence,263, 270 but a recent meta-
analysis estimated the annual recurrent stroke risk to be ≈4.26% without any 
observable decline over time.266 A study from the Dijon Stroke Registry reported an 
increase in recurrent strokes due to improved stroke care and more stroke survivors 
with longer survival, which is relevant with populations ageing in industrialized 
countries.270 On the other hand, a Swedish study found a reduction in incidence of 
both first and recurrent stroke, concluding that there were no indications of an 
increased stroke burden.269 More studies are needed on this matter.  
 
Factors associated with long-term recurrent stroke 
In paper II, we investigated the factors associated with recurrent ischemic stroke or 
TIA in our population and found that age, prior stroke, hypertension and chronic 
infarcts on MRI were predictors of recurrence. Hypertension at index event was the 
strongest risk factor for long term recurrence in paper II, with a HR of 1.65 (95% CI 
1.21-2.25). In one of the first longitudinal studies on stroke recurrence from 
Framingham, Sacco et al. found that the presence of hypertension at index was 
strongly associated with the risk of recurrence, especially in men.188 In a publication 
based on the Northern Manhattan Stroke Study, Sacco et al found that hypertension 
was a predictor of overall recurrence with a HR of 1.6 (95% CI 1.01-2.6).194 Mohan 
et al. found that hypertension increased the risk of recurrence at 5 years with a HR of 
 
 
1.47 (95% CI 1.1-2.0).160 Erikson and Olsson found systolic blood pressure as a 
predictor of recurrent stroke, with an OR of 1.005 (95% CI 1.003-1.007) per mm Hg 
increase.260 In several studies that reported hypertension as a predictor of long-term 
recurrence, the impact of hypertension was quite similar to our findings.  
Since patients with ischemic stroke or TIA are as previously mentioned at high risk of 
suffering another stroke compared to the general population, it is not unexpected that 
prior ischemic stroke or TIA and chronic infarcts on MRI was a predictor of long-
term recurrence in paper II. Most studies on long-term recurrence in table 4 included 
only patients with “first stroke”, which implies that these patients did not have 
ischemic stroke or TIA prior to inclusion.15, 160, 168, 172, 173, 178, 201, 207, 258, 261. Still, some 
studies have assessed the impact of prior stroke on long-term recurrence. In the study 
by Eriksson et al., 23.3% of patients had a history of stroke and prior stroke was a 
predictor of recurrence with a OR of 1.52 (95% CI 1.03-2.23).260 In the study by 
Edwards et al. prior stroke had a HR of 5.1 (95% CI 4.8-5.5) for a new stroke 5 years 
post-stroke compared to stroke-free matched controls.264 No other studies on long-
term recurrence included chronic infarcts on MRI in their analysis. Several studies 
have examined the concept of silent brain infarction (SBI). Leary et al. estimated that 
SBI is far more common than symptomatic lesions, with approximately 11 million 
first ever SBI´s in the US in 1998, compared with 770.000 symptomatic 
infarctions.271 In our study population, we were not able to discriminate between 
symptomatic and silent lesions. Thus, according to our findings, the presence of a 
chronic infarct on MRI in a patient with incident stroke or TIA, is suggesting a 
heightened risk of recurrent stroke. 
Although we did not find male sex as a predictor of having recurrent ischemic stroke 
or TIA at the p<0.05 level, several other publications have reported this association. 
As mentioned previously, males have a higher stroke incidence than females,94 but 
whether this also applies to recurrent stroke or not is unclear. In the early publication 
from the Framingham study, the risk of recurrence adjusted for age was significantly 
higher in males than females (42% vs 24%).188 Meissner et al. reported 5-year 
recurrence rates of 21% for men and 17% for women.258 A study by Moroney et al. 
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reported on the contrary that female sex was a predictor of recurrent stroke during a 
follow-up period of up to 59 months.272 Several other studies have reported similar 
recurrence rates between males and females.15, 178, 260  
In contrast to 30-day recurrence (Paper I), stroke subtype was not a predictor of long-
term recurrence in our study. This is in line with most other studies on long-term 
recurrence,15, 160, 173, 194, 198, 207, 262 although Hata et al. reported that CE had a higher 
10-year recurrence rate than lacunar infarction (HR 1.76, 95% CI 1.00-3.11). Some 
studies have claimed that lacunar stroke carried a better prognosis than other 
subtypes, but this in not supported by the currently available studies on long-term 
recurrence.204 
Several other studies have found cardiac disease a risk factor for long-term recurrent 
stroke. Sacco et al. found in the Framingham study that cardiac comorbidity was 
associated with an increased risk of recurrence.188 Viitanen et al. found cardiac failure 
to be associated with recurrent stroke.259 Modrego et al. found patients with 
combination of AF and other cardiac disease to have increased risk of recurrence with 
cardioembolic stroke.185 Mohan et al. found AF as a risk factor of 5-year 
recurrence.160 In general, cardiac disease may be seen as a result of underlying 
atherosclerotic, hypertensive and inflammatory processes which also play a major 
part in the formation of cerebrovascular disease. Thus, an association between cardiac 
disease and stroke recurrence is likely.  
Several other factors such as smoking, alcohol overuse, diabetes and stroke severity 
have been inconsistently associated with long-term recurrence in studies in table 4, 
but was not significant predictors in our patients.  
Table 5 demonstrates the incidence of all 277 recurrent ischemic stroke or TIA from 





Table 5, incidence rates of all recurrent ischemic stroke or TIA by year after 
index. 






95% Conf. Interval 
 
   
0   -   1 1741.8 118 67.7 56.6 - 81.1 
1   -   2 1608.1 51 31.7 24.1 - 41.7 
2   -   3 1476.2 31 21.0 14.8 - 29.9 
3   -   4 1192.6 30 25.2 17.6 - 36.0 
4   -   5 867.8 20 23.0 14.9 - 35.7 
5   -   6 605.9 13 21.6 12.4 - 37.0 
6   -   7 395.7 8 20.2 10.1 - 40.4 
7   -   8 219.1 5 22.8 9.5 - 54.8 
8   -   9 65.2 1 15.3 2.2 - 108.9 
>   9 0.5 0 0.00 . - . 
Total 8172.9 277 33.9 30.1 - 38.1 
 
By this method, the recurrence rate is especially high the first year of follow-up, with 
more similar rates the following years.  
 
Mortality 
In paper II, 36% of the cohort died during follow up, resulting in cumulative all-cause 
mortality of 10.7% at 1 year 33.5% at five years after index ischemic stroke or TIA. 
As the risk for recurrence, the risk of death was the highest early after index. This is 
also reported in other studies that have reported an elevated mortality risk especially 
the first year after stroke, ranging up to 10 times higher compared to the general 
population in some studies32, 42, 273-276. In 1-year survivors, the subsequent mortality 
risk seems lower, but all-cause mortality after ischemic stroke is considerably 
elevated years after the event in comparison with the general population. Hardie et al. 
reported an annual death rate of 4.8% among 1-year survivors of stroke, 2.3 times 
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greater than for the general population.33 In a study that compared long-term 
mortality after ischemic stroke with age-matched controls, Carter et al. reported a 
more that 3-fold risk of death in ischemic stroke patients.277 In a Norwegian study, 
Mathisen et al. found a HR of 2.2 for death long-term after ischemic stroke, 
compared with stroke-free individuals.43 Other studies have also reported a 2-3 times 
higher long-term mortality after stroke compared with the general population.31, 273, 274   
Table 6 demonstrates reported 5-year mortality rates across studies on long-term 
mortality after stroke. Most studies are based on cohorts followed in the 1980s and 
1990s, with just a few recent studies. Although there are differences in populations 
and inclusion of ICH, the reported mortality rates are strikingly similar. Only 5/17 











Sacco, 1982 48/40 Framingham 
Schmidt, 1988 72.1 Stroke Registry 
Kojima, 1990 60.8 Community-based 
Dennis, 1993 45 OXVASC 
Sacco, 1994* 45 NOMAS 
Petty, 1998* 52.9 Rochester 
Hankey, 2000 60.1 PCSS 
Brønnum-Hansen, 2001 60.0 WHO MONICA 
Hartmann, 2001* 41 NOMAS 
Kiyohara, 2003 59.7/67.7 Community-based 
Hardie, 2003 59 PCSS 
Bravata, 2003* 52.6 Administrative 
Vernino, 2003* 54 Population-based 
Kammersgaard, 2006 54.8 Copenhagen Stroke Study 
Wolfe, 2011 57.2 Stroke Registry data 
Ray, 2013 59.4 Community-based 
Mathisen, 2016 26.7 Stroke unit 
* Denotes studies on ischemic stroke only. Abbreviations: OXVASC, Oxford 
Vascular Study and the Oxfordshire Community Stroke Project; NOMAS, Northern 
Manhattan Stroke Study; PCSS, Perth Community Stroke Study; FUTURE, 
(Follow-Up of Transient Ischemic Attack and Stroke Patients and Unelucidated 
Risk Factor Evaluation) study; WHO MONICA (Multinational Monitoring of 
Determinants and Trends in Cardiovascular Disease) Project;  
 
Mortality after stroke is mainly due to cardiovascular causes and is consistently 
associated with cardiovascular risk factors across studies.15, 33, 39, 42, 45, 188, 194, 273, 274, 276, 
278-282 One of these cardiovascular causes is recurrent stroke, but despite recurrence 
being frequent and devastating, few studies have assessed the impact recurrent stroke 
has on all-cause mortality. In one of the first studies investigating this matter, Sacco 
et al. found no difference in mortality for incident ischemic stroke compared with 
those with prior stroke in the NOMAS study.194 Jorgensen et al. found in the 
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Copenhagen Stroke Study that mortality was almost doubled in patients with 
recurrence compared with patients with a first-ever stroke (OR 1.8 (95% CI 1.26-
2.66)).217 Several other studies have also reported increased mortality after 
recurrence. Petty et al. found that recurrence tripled the risk of death after first 
cerebral infarction in a population from Rochester, Minnesota (RR 3.0 (95% CI 2.5-
3.5)).15 Lisabeth et al. reported that recurrence increased the risk of mortality with a 
risk ratio of 2.67 (95% CI 1.90-3.76) in a Hispanic and white population.218 In a 
recent Finnish study on young stroke patients, Aarnio et al. found that recurrent 
stroke was the most important risk factor for mortality after first-ever ischemic stroke 
(HR 16.68 (95% CI 2.33–119.56).219 These studies differ in populations, time periods 
and importantly – statistical methods. Since the risk of recurrence varies by time after 
the index event, it violates the proportional hazards assumption in the Cox regression 
model. If this problem is not taken into account in the model, then the regression 
result will not be valid for this factor. This is usually solved by including this factor 
as a time-varying covariate in the Cox model. Two of the mentioned studies, by 
Lisabeth et al. and Petty et al., addressed this issue and adjusted their regression 
analyses accordingly. Their results are similar and in line with our findings.  
Recurrence seems to impact mortality by increasing disability. Stroke severity, 
manifested as the neurological deficits or degree of disability, is considered the most 
important factor affecting mortality in stroke patients.44, 278, 283 When ischemic stroke 
adds on to existing disability from any cause, it increases mortality, both short- and 
long-term. Kwok et al. found in a study from the UK that prestroke disability 
predicted inpatient mortality independent of stroke type and severity.284 Hankey et al. 
found in the Perth Community Study that a reduced Barthel Index (<20), doubled the 
long-term mortality risk.273 In a recent publication from OXVASC, Ganesh et al. 
found increasing 5-year mortality for every point increase in pre-stroke modified 
Rankin Scale.285 Unfortunately, most trials on thrombolysis in acute stroke excluded 
patients with a modified Rankin Scale ³2.285 This has been implemented in the 
European guidelines as a recommendation that primarily patients with a premorbid 
 
 
modified Rankin Scale 0-1 should be eligible for acute interventions.286 The 
implication of this practice is that patients with a substantial prestroke morbidity is 
adding even more disability which a subsequent increase in mortality.  
 
Secondary prevention of ischemic stroke or TIA 
In paper II, we demonstrated that the patients in our study had high rates of 
prescribed secondary prevention therapies such as antiplatelet or anticoagulant 
treatment, lipid-lowering drugs and antihypertensive drugs. Ideally, all patients 
should receive the optimal combination of secondary prevention and adhere to it for 
maximal risk reduction. This is not always the case due to differences in factors like 
guideline adherence, drug adherence and tolerance, or incomplete stroke evaluation. 
As previously mentioned, there is evidence that optimal secondary prevention is 
associated with a lowered risk of stroke, major vascular events or death.26, 167, 287 Still, 
little is known about the rates and trends of secondary preventions therapies after 
ischemic stroke across countries and populations. In a publication from the PURE 
study, Yusuf et al. found higher rates of secondary prevention therapies in high-
income countries (e.g. Sweden) compared to low-income countries.288 Data from the 
OECD Health Statistics database demonstrate significant differences in drug 
consumption between the European countries.289 According to this report, 
consumption of antihypertensives was below average for the Norwegian population 
as a whole in 2015-16, while consumption of lipid-lowering drugs was significantly 
above average.290 In patients with ischemic stroke or TIA in Norway, national data on 
dispensing of secondary prevention drugs in cardiovascular disease has been only 
recently available. Figure 3 demonstrates the percentage of patients with recent 
ischemic stroke or TIA that filled their prescription of different drug classes within 90 
days after hospital discharge in 2012-13.291 Nationwide, over 90% with ischemic 
stroke filled their prescription of antithrombotics (B01) within 90 days. The rates in 
TIA patients were slightly lower. Compared to the national data, patients in paper II 
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had higher prescription rates for antithrombotics, but similar prescription rates for 
both lipid-lowering drugs (C10) and antihypertensive drugs (C08-09).  
Despite the fact that most patients are prescribed secondary prevention, we do not 
know if the patients actually were taking all or some of their prescribed drugs. In the 
stroke unit at Haukeland University Hospital, most patients are followed up after 3 
months by a stroke neurologist in an out-patient setting where drug compliance or 
changes in prescriptions are noted. In this setting, most patients seem to adhere to 
their medications. Otherwise, patients are followed up in general practice, where the 
intensity of follow-up is both physician- and patient-dependent. On the other hand, 
our recurrence rates are in the anticipated range with regards to the expected effects 
of secondary prevention therapies. Older studies on the natural history of ischemic 
stroke before secondary prevention, showed 5-year recurrence rates of around 40%. 
This may suggest that patients in our cohort comply with their secondary prevention 
therapies.  
Studies demonstrate that many patients do not adhere to secondary prevention 
therapies. In a meta-analysis of non-adherence to secondary prevention after stroke or 
TIA, Al AlShaikh et al. found that the non-adherence rate was 30.9% across 16 
included studies.292 A meta-analysis by Chowdhury et al. found that suboptimal 
adherence to cardiovascular mediations in patients with cardiovascular diseases, 
including stroke, is responsible for around 9% of all cardiovascular events in 
Europe.293 Sappok et al. reported that compliance with secondary prevention after 
stroke in an urban German population was better especially in patients with higher 
age, more severe neurological deficits and cardioembolic stroke.294  
Even when patients comply with their secondary prevention therapies, many patients 
do not reach the recommended target values for blood pressure or lipids. In a recent 
Norwegian study from a General Practice, 47% of patients reached their target blood-
pressure and 27% their target low density lipoprotein (LDL) cholesterol target value 




Figure 2: Norwegian national dispensing data for secondary prevention 
drug classes (WHO Anatomical Therapeutic Chemical Classification (ATC) 
B01-C10) in ischemic stroke (top) and TIA (bottom) survivors, stratified by 
age group and sex. Percentage (%) of patients that filled their prescriptions 
within 90 days after ischemic stroke or TIA discharge in 2012-2013.291   
 
 
Left: Patients 35-75 years of age. Right: patients between 76-85 years of age. Blue: 
men. Red: women. ATC drug classes: C10, Statins and other lipid-lowering drugs; 
C09, ACE inhibitors/Angiotensin II-receptor blockers including combinations with 
diuretics; C08, Calcium antagonists; C07, Beta blockers; C03, Diuretics; C01, 
Cardiac medications; B01, Antithrombotics. 





In paper III we estimated the incidence of stroke mimics after ischemic stroke or TIA.  
Our study is the first to calculate the cumulative risk of stroke mimic in a stroke 
population. Stroke mimic patients represent up to 40% of all patients admitted with 
suspected stroke.222 Many studies have observed that patients with stroke mimics 
have fewer ischemic stroke risk factors.220, 226, 296, 297 Prior studies have quantified the 
incidence of stoke mimics by reporting the proportions of stroke mimics in all 
suspected strokes in admitted to emergency departments or stroke units. About one of 
12 patients had been admitted with a stroke mimic within the first year and one of six 
patients had been admitted within five years after the index stroke.224, 298  
In our study, patients with stroke mimics had more often hypertension at the time of 
the index stroke. Patients with hypertension are susceptible to both severely elevated 
blood pressure that can cause neurological symptoms, as well as hypotension due to 
intake of vasoactive drugs, which may lead to unexpected drops in blood pressure 
with altered consciousness, dizziness and syncope. Diabetes was also more common 
in patients with stroke mimics. Hypo-/hyperglycemia can produce a wide array of 
focal and global neurological signs. We did not, however, register blood pressure 
levels or serum glucose levels for each admission and could not examine these 
factors.  
We found a multitude of stroke mimic diagnoses after ischemic stroke. In paper III, 
due to article length restrictions, only the seven most common diagnoses were listed. 
Table 7 demonstrates all the different stroke mimic diagnoses in paper III, except the 






Table 7: Frequency of stroke mimic diagnoses and the corresponding ICD-
10 codes at discharge 
Diagnoses N ICD-10 
Sequelae of cerebral infarction 95 I69.3 
Medical observation and evaluation for 
suspected cerebrovascular disease 75 Z03.3 
Infections 67 N39, J18, J06, A41, 
Epilepsy and recurrent seizures 46 G40, R56 
Dizziness and vertigo 40 H81, H83, R42 
Migraine and other headaches 37 G43, R51 
Syncope and collapse 34 I95, R55, 
Other diagnoses (n=1 each) 17 miscellaneous 
Disorientation and confusion 13 G45, R41, F03 
Heart disease (CHD, heart failure, arrhythmias) 12 I21, I50, I45 
Falls and injuries 10 S06, S52, S72, W19, 
Hemorrhagic complications (GI, extra-axial 
ICH, other) 9 H11, I62, K92 
Drug side-effects 8 Y4n 
Cancer 5 C00-C97 
Diabetes 4 E10-E14 
Venous thromboembolic disease (pulmonary, 
cerebral sinus) 3 I26, G08 
Depression/anxiety 3 F30-F48 
Anemia 2 D50-D53 
Abbreviations: N, Number; ICD-10, International Classification of Diseases, Tenth 
Revision; CHD, coronary heart disease; GI, gastrointestinal; ICH, intracerebral 
hemorrhage;  
 
Admissions with suspected stroke after ischemic stroke or TIA were common in our 
study population and the risk is also highest shortly after index stroke discharge.299 
Fear of recurrent stroke is also common among stroke patients. In a small study by 
Townend et al. 50 out of 89 stroke survivors were worried about suffering another 
stroke.300 Although there seem to be no data on this subject, one implication of fear of 
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recurrent stroke may be that stroke survivors are more prone to seek acute medical 
help for new or re-expressed symptoms. One could also hypothesize that the fear 
would naturally be most intense shortly after the stroke. This may thus provide an 
explanation on why the two most common and unspecific diagnoses were especially 
frequent in the first months and year after the index event.   
The most common specific stroke mimic in our study was infection. An infection 
may cause stroke-like symptoms if it affects a patient’s consciousness directly, such 
as meningitis or encephalitis, or by the phenomenon of re-expression of prior stroke 
symptoms, or post-stroke recrudescence.228, 301, 302 Infections are frequent after stroke, 
partly because of immunodepression caused by central nervous system damage and 
also the direct effects of stroke, such as the risk of aspiration.303, 304 Because blood 
tests and identification of infectious agents are time-consuming procedures, these 
patients may end up being treated with thrombolysis or hospitalized even with simple 
infections. Few studies have investigated long-term incidences of common infections 
after stroke. A Norwegian study on readmissions up to 10 years after stroke found 
that infections were the cause of 17.3% of post-stroke readmissions, peaking in 
incidence about 6 months after stroke with a subsequent stabilization in incidence.303 
We found the same pattern in frequency for infections as stroke mimics.  
The second most common specific stroke mimic was seizures and epilepsy. Seizures 
are common stroke mimics and are challenging to distinguish from acute stroke as 
they may cause focal neurological symptoms, as well as altered consciousness.221 
Seizures/epilepsy peak in occurrence between 6 and 12 months after stroke,305 and the 
same peak is observed for seizures as a stroke mimic in our study.  
Both dizziness/vertigo and syncope/collapse are common stroke mimics, as they may 
produce neurological symptoms that are difficult to separate from acute stroke.221, 223 
In our study, these mimic diagnoses were spread out over the follow-up period 
without any clustering early after index stroke. One explanation for this might be that 
these symptoms are common in an ageing population. They are often caused by a 
 
 
general decline of the vestibular system function, leading to vertigo, imbalance and 
falls, and not necessarily affected by the index stroke.306  
We found migraine and other headaches, which often are suspected to be a symptom 
of extra- or intra-axial hemorrhages after stroke, to be a common stroke mimic in our 
population. Migraine with aura is considered a risk factor for stroke.307, 308 Moreover, 
migraine is also the third most common stroke mimic and a frequent cause for 
erroneous thrombolysis.309 Because both migraine and ischemic stroke are prevalent 
diseases, the difficulty of discerning a migraine attack from an ischemic event is 
commonplace in a stroke unit. Besides, while thrombolysis in migraine patients is 
considered safe,309 this applies primarily to patients without prior stroke.  
Most stroke mimics diagnoses in paper III were done without exclusion of diffusion 
restriction abnormalities on MRI. Although almost 90% of patients underwent brain 
imaging, most of them were examined only with CT, which have lower sensitivity for 
acute stroke detection, especially in the early phase. Accordingly, most stroke mimics 
diagnoses were made by a combination of clinical judgment and other diagnostic 
modalities, like blood tests, EEG etc. This implicates that we cannot exclude that 
some ischemic stroke or TIA events may have been missed, which would 
overestimate the incidence of stroke mimics and underestimate the incidence of 
recurrent ischemic stroke or TIA. On the other hand, most patients were treated in a 
stroke unit by an experienced stroke neurologist and the results in paper III is thus the 
expression of their clinical judgment and their real-world use of imaging studies. 
Many of the diagnoses in table 7 seem to be possible to diagnose without the need of 
excluding stroke on DWI-imaging.  
In other studies, some authors have used the term ”neuroimaging-negative” ischemic 
stroke for patients that were thought to have ischemic stroke, but lacked diffusion 
restriction abnormalities on DWI-MRI after rapid treatment with tPA.297, 310, 311 We 
cannot exclude that this may have occurred in some of the 38% of stroke mimic 
patients with a negative DWI-study, but according to a study by Freeman et al., this 
phenomenon is very rare.312  
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The process of ruling out ischemic stroke in a patient with acute focal neurological 
signs often requires observation combined with brain imaging, due to the non-specific 
nature of neurological symptoms. This indicates that hospitalization of stroke mimics 
is impossible to avoid entirely, but better education of patients, family and healthcare 
professionals may have the potential to avoid unnecessary admission after ischemic 
stroke, especially in the early phase. 
 
Future perspectives 
Over the last decades, there has been an improvement in acute ischemic stroke 
treatment, improved control of cardiovascular risk factors and an increase in life 
expectancy both in Norway, and in many other populations.27, 99, 313, 314 This implies 
that ischemic stroke patients in the future will live longer, with less neurological 
sequelae and have a higher quality-of-life. These patients are projected to suffer both 
more recurrences and more hospital admissions with stroke mimics.223 Knowledge 
about the risk, the risk factors and the consequences of recurrence and stroke mimics 
is of value for every clinician treating ischemic stroke patients.  
In most stroke units, the standard evaluation for acute stroke at admission is CT with 
or without contrast angiography, which is excellent to exclude hemorrhages and other 
pathologies, but have lower sensitivity for detection of acute ischemic stroke. Some 
have advocated the use of CT perfusion and especially diffusion-weighted MRI to 
discriminate between acute ischemic stroke and stroke mimics,315, 316 but there are 
still several issues with implementing more advanced imaging modalities in an acute 
stroke protocol, such as costs and availability. However, implementation of such 
diagnostic modalities in acute stroke evaluation could potentially reduce possibly 
harmful recanalization therapy of patients with stroke mimic shortly after ischemic 
brain injury.  
 
 
Now that we see the evolution of personalized medicine, assessment of a patient’s 
risk combined with their genetic profile will open new possibilities for individually 
tailored and even more effective secondary stroke prevention. Because in contrast to 
acute ischemic stroke therapies, few novel therapies have been adapted for secondary 
prevention the last decades. There are a few glimpses of hope though. Recently, 
studies on both novel therapies and combination of existing therapies have shown the 
potential to significantly reduce the risk of recurrent cardiovascular events compared 
with existing therapies. A study on reducing inflammation in patients with 
atherosclerotic disease with a monoclonal antibody demonstrated a major reduction in 
cardiovascular events after 48 months.317 Monoclonal antibodies that inhibits 
proprotein convertase subtilisin–kexin type 9 (PCSK9) have the potential to lower 
LDL-cholesterol levels far below the current LDL-level treatment goals, thereby 
reducing the risk of recurrent cardiovascular events even more than with statin 
therapy.318, 319 Another recent study showed a benefit of adding low-dose 
anticoagulant therapy (rivaroxaban) to aspirin for the reduction of cardiovascular 
outcomes in patients with stable cardiovascular disease.320  
Recurrent ischemic stroke or TIA will never be eradicated, but with preventive 
measures focusing on known and future risk factors, as well as evolution of more 
effective preventive therapies, more patients will have a hope of a good life quality 









Strengths and limitations of the thesis 
Our studies have several limitations. Firstly, all papers included in this thesis are 
registry-based and the information in our registry as well as most other registries is 
gathered without any specific hypothesis in mind. Furthermore, regular medical 
electronic records data are not intended for research, and may thus be more prone to 
error and misclassification. The acquired data may also be insufficient to answer all 
the relevant scientific questions in a study and the analyses may thus be subject to 
unmeasured confounding. E.g. we have no information about the patient’s adherence 
to secondary prevention therapies or risk factor burden in-between the admissions. 
Secondly, the NORSTROKE study is single-center and hospital based, and mainly 
covers a Caucasian population. Thus, our results may not be applicable to other 
demographics. Thirdly, patients are not followed as close as in a clinical study which 
means that recurrent events may be underestimated. Since hospitalization to specific 
hospitals was necessary for recurrent event identification, clinical events that were 
admitted to hospitals outside of Western Norway or even not hospitalized at all, were 
not identified. This may underestimate our recurrence rates. In our experience, not all 
strokes in patients with poor functional status that live in nursing homes are 
hospitalized. This may also be the case with patients already on maximum secondary 
prevention, or patients with end-stage cancer. Since we have no information about 
cause-specific-mortality, death of ischemic stroke without a hospital admission (e.g. 
patients living alone who were not able to alert the medical services) would also not 
be identified as recurrence in our study.  
One of the main strengths of our studies is decades of electronic medical records 
manually accessed and collected for each patient. This ensures more precise and 
diverse information than automatically mined data like administrative codes used for 
research. Because all acute stroke in Norway is treated in the public health system, 
this may reduce selection bias and make the present data better transferrable to a 
general population. Moreover, identification of new clinical events that led to 
 
 
hospitalization could be ensured for a large geographical area by the use of electronic 
records. Lastly, comprehensive data on medications for each patient is often not 
available in non-clinical studies. Thus, assessment of secondary prevention therapies 
in a hospital-based population gives real-life data which is an important supplement 




In this thesis, we have demonstrated modest rates of clinical recurrent ischemic stroke 
or TIA in our hospital-based population, both short- and long term, compared with 
most other previously studied populations. The risk of recurrence was highest shortly 
after ischemic stroke or TIA and remained elevated for the first 1.5 years after the 
event, with subsequent stabilization. Being admitted to a hospital with a stroke mimic 
was almost twice as common as suffering a recurrent ischemic stroke or TIA in the 
same time-period. The risk of stroke mimics was also highest early after index 
ischemic stroke or TIA. Patients admitted to a hospital with suspected stroke were 
more likely to have a stroke mimic than recurrent ischemic stroke or TIA, especially 
the first two years after the index event.  
The risk of early recurrence among stroke subtypes was highest for patients with 
ischemic stroke or TIA due to stroke of other etiology (SOE) and large-artery-
atherosclerosis (LAA). In the former category, most patients had malignancies as the 
cause of their early recurrent ischemic stroke or TIA. We found no association 
between the risk of long-term-recurrence and stroke subtype.  
Known cardiovascular risk factors were associated with recurrent ischemic stroke or 
TIA. For 30-day recurrence, patients with a history of peripheral artery disease were 
more likely to suffer an early recurrent ischemic stroke or TIA. For long-term 
recurrence, patients with a history of hypertension, prior symptomatic ischemic stroke 
or TIA and visible chronic infarcts on MRI were more likely to experience a recurrent 
ischemic stroke or TIA.  
About one third of our cohort died during follow-up. Suffering a recurrent ischemic 
stroke or TIA more than doubled the mortality risk.  
We demonstrated that stroke mimics were common after suffering an ischemic stroke 
or TIA. The etiologies behind these stroke mimics were diverse and similar to 
 
 
etiologies in patients with stroke mimics without prior ischemic stroke or TIA. The 





1. Norwegian Stroke Research Registry Inclusion Form Excerpt 
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Page 19: Patient data on medications at index event admission and 
discharge 




Bakgrunnsopplysninger – tidligere sykdom 
 
Tidligere cerebrovaskulær sykdom  
 Ja Nei Ukjent Antall Debutår Måned / år for siste 
«Hjerneslag»    
   
Hjerneinfarkt      /  
Hjerneblødning      /  
Uspesifisert      /  
TIA      /  
 
TIA siste 24 timer?  Klokkeslett :  
Siste uke Dato / /  
1-4 uker før slaget Dato / /  
4-12 uker før slaget Dato / /  
>12 uker før slaget Dato / /  
 
Tidligere sykdommer 
 Ja Nei Ukjent Debutår   
NHR: Gjennomgått store hjerte-/ 
karintervensjoner?     * Hvis karintervensjon Ja 
Hjerteinfarkt     Innen siste uke  
Angina pectoris     1-4 uker før slaget  
Koronar intervensjon *     4-12 uker før slaget  
Aortaventil *     >12 uker før slaget  
Annen hjertesykdom     
  
Carotisstenose      
  
Carotisoperasjon/stent *     
  
Perifer karsykdom / inkl. aorta     
  
Perifer karkirurgi/intervensjon *     
  
Lungeemboli      
  
Dyp venetrombose      
  
Hypertensjon     
  
Diabetes mellitus     
  
Dyslipidemi     
  
Atrieflimmer – paroksystisk     
  
Atrieflimmer – kronisk     
  
Migrene     Lungecancer  
Demens     Brystcancer  
Depresjon (medikamentelt behandlet)     Gastrointestinal cance  
KOLS (kronisk obstruktiv lungesykdom)     Urogenital cancer  
Cancer     Î Annen cancer  
 
 





Bakgrunnsopplysninger – før sykehusinnleggelsen 
 
Røykevaner 
 Aldri   
 Eks-røyker:   Sluttet år  
 Røyker:   Antall sigaretter per dag  
 Ukjent   
 
Alkoholvaner  
 Avholdende   
 Alkoholmisbruk nå   
 Alkoholmisbruk tidligere:   Sluttet år  
 






Funksjonsstatus (modifisert Rankin Scale) 
 
0 = Ingen symptomer og ingen begrensninger i dagliglivet 
1 = Lette symptomer, men i stand til å utføre alle vanlige aktiviteter 
2 = Begrensninger i sosiale aktiviteter, men uavhengig i ADL 
3 = Har behov for noe hjelp (instrumental ADL), men kan gå uten hjelp 
4 = Kan ikke gå uten hjelp, trenger hjelp i daglige aktiviteter (basic ADL) 
5 = Sengeliggende, inkontinent, avhengig av kontinuerlig hjelp 
 
Boligforhold   Bosituasjon 
 Egen bolig uten hjemmesykepleie/-hjelp  Bodde alene  
 Egen bolig med hjemmesykepleie/-hjelp  Bodde sammen med noen 
 Omsorgsbolig  Bodde i institusjon/sykehjem 
 Sykehjem  Ukjent 
 Ingen fast bopel   
 Bor med familie (f.eks. generasjonsbolig)   
 Ukjent   
 
Sivil status  Arbeidsstatus  
 Ja Nei   Ja Nei 
Gift/samboende    I arbeid/utdanning   
Enke/enkemann    (hel eller deltid)   
Enslig    
Ukjent    
 
Utdanning (høyeste fullført) 
 Grunnskole   Videregående  3 år univ./høyskole   5år univ./høyskole  
 
Gravid Ja Nei Trimester 1 2 3 Partus dato 
        / /  
 






Stoffgruppe: Medikament Før slaget Ved utreise 
 
 Ja Nei ? Dose Ja Nei ? Dose 
Acetylsalicylsyre: 
   
 
   
 
ADP-blokker:  
   
 
   
 
Dipyridamol: 
   
 
   
 
Warfarin: 
   
 
   
 
LMW heparin: 
   
 
   
 
Faktor Xa inhibitor: 
   
 
   
 
Trombin inhibitor: 
   
 
   
 
Diuretikum: 
   
 
   
 
ACE-hemmer: 
   
 
   
 
A2-antagonist: 
   
 
   
 
Beta-blokker: 
   
 
   
 
Ca-antagonist: 
   
 
   
 
Alfa-blokker: 
   
 
   
 
Statin: 
   
 
   
 
Annen lipidsenker: 
   
 
   
 
Insulin: 
   
 
   
 
Antidiabetikum po: 
   
 
   
 
Østrogener: 
   
 
   
 
Hormonspiral: 
   
 
   
 
p-pille: 
   
 
   
 
Nikotinerstatning: 
   
 
   
 
Antidepressivum: 
   
 
   
 
Antidemens: 
   
 
   
 
Thyroxin: 
   
 
   
 
Antiepileptikum:  
   
 
   
 
«Medikamentell behandling for høyt blodtrykk» 
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The purpose of diagnostic evaluation of acute stroke is identification 
of the causal etiology behind it, in order to reduce the risk of further 
strokes with appropriate secondary prevention. Recurrent stroke is 
associated with increased disability and mortality compared to the 
index stroke (Petty et al., 1998; Sacco, Wolf, Kannel, & McNamara, 
1982). And even with appropriate prevention, the risk of recurrence 
after ischemic stroke (IS) and transient ischemic attack (TIA) is high, 
especially in the early phase after stroke (Lovett, Coull, & Rothwell, 
2004; Sacco, Shi, Zamanillo, & Kargman, 1994). Paradoxically, many 
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Abstract
Background: Incidence of recurrent stroke is highest within 30 days after the initial 
ischemic stroke (IS) or TIA, but knowledge about early recurrence is lacking. We 
aimed to identify etiological groups with highest risk of early recurrence and assess 
how the TOAST classification identified index stroke etiology.
Methods: Medical records of 1874 IS and TIA patients in the Bergen NORSTROKE 
registry were retrospectively reviewed for identification of recurrent IS or TIA within 
30 days after index IS or TIA. Stroke etiology was determined by review of electroni-
cal medical journals. Logistic regression was used to calculate odds ratios (OR) for 
30-day recurrence.
Results: Thirty-three patients (1.8%) were readmitted with recurrent IS or TIA within 
30 days after index stroke. By using TOAST, 12 patients were initially classified with 
stroke of unknown etiology (SUE). Etiologies behind recurrent IS or TIA were after 
the recurrent episode identified as extracranial large artery atherosclerosis (LAA) in 
14 patients (42.4%), intracranial arterial pathology in seven patients (21.2%), active 
malignancy in six patients (18.2%), and cardio embolism in four patients (12.1%). 
Small vessel occlusion and SUE were the causes in one patient each. Logistic regres-
sion showed that patients with stroke of other determined etiology (SOE) and LAA 
had increased risk of 30-day recurrence (OR = 9.72, 95% CI 1.84–51.3, p < 0.01 and 
OR = 4.36, 95% CI 2.01–9.47, p < 0.01, respectively).
Conclusion: Patients with LAA and SOE had increased risk of recurrent IS or TIA 
within 30 days. TOAST was inadequate at identifying exact etiologies behind recur-
rent stroke at index event.
K E Y W O R D S
cerebrovascular disease, ischemic stroke, readmission, stroke etiology, stroke recurrence
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occurring within the first month leaving a lack of data regarding early 
recurrence (Coull & Rothwell, 2004). Studies on 30-day recurrence 
are scarce and use varying definitions of recurring events. A meta-
analysis found a pooled cumulative risk of 3.1% for 30-day recur-
rence, but risk estimates of 30-day recurrence vary greatly (Mohan 
et al., 2011). Moreover, when classifying etiology by TOAST, around 
40% of patients will end up with an undetermined or cryptogenic eti-
ology when an apparent cause is lacking or identification of multiple 
competing etiologies (Hart et al., 2014). Most recurrent IS is of the 
same type as the index episode, except for lacunar IS, which seems 
especially true for early recurrence (Jones, Sen, Lakshminarayan, & 
Rosamond, 2013; Yamamoto & Bogousslavsky, 1998). This impli-
cates that patients with the highest risk of early recurrence may not 
obtain a specific etiology and thus not receive the most effective 
secondary prevention. A better understanding of causes behind 
early recurrence is therefore of utmost importance, as it may opti-
mize prevention and thereby reduce morbidity and mortality.
We aimed to determine the etiology in patients rehospitalized 
with recurrent IS or TIA within 30 days after index stroke onset. We 
also aimed to identify etiological groups with the highest risk of early 
recurrence and see how TOAST identified the etiologies at index.
2  | METHODS
All patients older than 18 years of age admitted with IS or TIA 
to the stroke unit at the Department of Neurology, Haukeland 
University Hospital, between July 1, 2007, and December 31, 
2013, were registered in the Bergen NORSTROKE registry. IS was 
defined as an episode of neurologic deficit lasting >24 hr where 
magnetic resonance imaging (MRI) or computed tomography (CT) 
showed infarctions related to the clinical findings (Johnson et al., 
1995). TIA was defined as a clinical diagnosis of transient focal 
cerebral dysfunction lasting shorter than 24 hr with no objective 
evidence of brain infarction on imaging (Johnson et al., 1995). All 
patients were investigated with brain imaging (CT and/or MRI), 
carotid ultrasound, and 24-hr electrocardiographic monitoring. 
Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria was 
used for etiology classification. TOAST classifies stroke as caused 
by large-artery atherosclerosis (LAA), cardio embolism (CE), small 
vessel occlusion (SVO), other determined cause (SOE), or stroke of 
undetermined cause (SUE; Adams et al., 1993).
Recurrent IS or TIA was identified by review of electronic 
medical records from Haukeland University Hospital unit and the 
other eight hospitals under the Western Norway Regional Health 
Authority, up to 30 days after completing evaluation and being 
discharged alive following the index IS or TIA from our stroke unit. 
New focal episodes from the same arterial territory during the ini-
tial hospitalization were considered as progression of acute stroke 
and not recurrence. We excluded patients who died before dis-
charge and patients discharged to palliative care. We did also not 
include intracerebral hemorrhage or subarachnoid hemorrhage as 
recurrence. TOAST etiology for the index IS or TIA was obtained 
from the Bergen NORSTROKE registry. Intracranial lesions were 
studied separately because it is challenging to discriminate be-
tween embolic and atherosclerotic intracranial arterial pathology, 
especially in the early phase after the initial stroke (Lee, Oh, Bang, 
Joo, & Huh, 2004).
After the recurrent IS or TIA, a new etiological evaluation by re-
view of supplemental clinical and imaging data was performed by 
two doctors with experience in stroke medicine (ANK and HN). A 
possible common cause for both episodes was determined.
The study was approved by the Western Regional Ethics 
Committee with written informed consent obtained from all patients 
or their legally authorized representatives.
2.1 | Statistics
Chi-squared test was used to assess baseline characteristics for cat-
egorical variables. Students’ t test or Mann–Whitney’s U test was 
used to investigate continuous variables and expressed as mean with 
standard deviation (SD) or as median with interquartile range (IQR) if 
skewed. Backward stepwise regression was used to investigate the 
significant factors associated with 30-day recurrence. Stata/SE 15.1 
(Stata Corp LLC) were used for the analyses.
3  | RESULTS
We identified 1874 patients who were discharged alive from our 
stroke unit after their index IS or TIA during the inclusion period, of 
whom 1668 with IS and 206 with TIA. CE was the most frequently 
determined cause of IS or TIA (n = 604, 32.3%), followed by LAA (N 
= 245, 13.0%), SVO (N = 205, 10.9%) and SOE (N = 32, 1.7%) during 
index admission. An etiology could not be determined in 42.1% of 
the patients.
A total of 33 patients, 28 with IS and five with TIA, (1.8%) were 
readmitted within 30 days after index stroke onset. Baseline char-
acteristics are shown in Table 1. Patients with recurrence more 
frequently had a history of peripheral artery disease, carotid endar-
terectomy, a shorter length of stay (LOS) and were more often dis-
charged home without assistance after the index event. There were 
no differences in age, gender, mRS at discharge, NIHSS score on ad-
mission, or treatment with IV thrombolysis between patients with 
30-day recurrent IS or TIA and patients with no recurrent stroke. 
Five patients that experienced new focal episodes from the same 
vascular territory during index admission, along with two patients 
that suffered early recurrence with hemorrhagic stroke, were ex-
cluded from the recurrence group.
Etiology as classified by the TOAST classification after the index 
event is shown in Table 1. LAA was the most frequent index etiology 
in patients with 30-day recurrence (n = 14), followed by intracranial 
vascular lesions (n = 8), CE (n = 5), SOE (n = 2), SVO (n = 1), and SUE 
(n = 12). Median time from index stroke to recurrence was 14 days 
(IQR 9, 20). No patient had TIA at both events. Ten patients self-re-
ported previous TIA symptoms. An MRI was performed in 29 of 33 
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patients at both index and recurrent event. Two patients had no MRI 
performed at any event.
After evaluating new clinical, radiological, and other investiga-
tive data after the recurrent event, specific etiology causing both 
index and recurrent IS or TIA could be identified in all but one patient 
(Table 2). Recurring stroke made a more specific classification in all 
except one patient with SUE from the index event possible. LAA of 
extracranial arteries was considered cause of both index and recur-
rent stroke in 14 patients (42.4%) instead of 13 at index. Six patients 
had experienced TIA symptoms previous to index admission. Eleven 
of 14 patients had a carotid stenosis >50% ipsilateral to the affected 
hemisphere. Five of 11 patients underwent carotid endarterectomy 
(CEA), four of them after the second stroke, and one after the first, 
with a median time from index stroke to surgery of 12 days (IQR 8, 
12). In one patient, an intima flap following CEA occluded the carotid 
artery causing a new IS within 30 days after index.
Seven patients (21.2%) had intracranial vascular lesions respon-
sible for recurrent stroke in the same vascular territory: three with 
stenosis of the middle cerebral artery (MCA), two with intracranial 
carotid stenosis, one advanced intracranial atherosclerosis, and one 
with an MCA aneurysm.
Six patients (18.2%) had recurrent IS or TIA because of hyperco-
agulability caused by underlying active cancer. Only one patient was 
recognized as having cancer-related stroke and classified as SOE at 
index event. Three were classified as CE and two as SUE.
Atrial fibrillation was the final cause of stroke in four patients 
(12.1%) instead of five classified at index. Two patients classified 




No 30‐day recurrence 
N = 1841 p
Age (years) mean ± SD 74.4 ± 11.5 73.2 ± 13.6 0.63
Sex (male) 17 (51.5) 1,019 (55.4) 0.66
mRS score, median (IQR) 1 (0, 2) 2 (0, 3) 0.06
NIHSS score, median (IQR) 1 (0, 4.5) 2 (1, 5) 0.09
BI score, median (IQR) 100 (100, 100) 100 (70, 100) 0.02
Index etiology (TOAST) <0.01
Atherosclerosis 13 (39.4) 232 (12.6) <0.01
Cardioembolism 5 (15.5) 599 (32.5) 0.03
Small vessel disease 1 (3.0) 204 (11.1) 0.14
Other determined 2 (6.1) 30 (1.6) 0.05
Undetermined 12 (36.6) 776 (42.2) 0.52
Comorbidities
Peripheral artery disease 7 (21.2) 129 (7.0) <0.01
Diabetes 6 (18.2) 275 (14.9) 0.61
Angina pectoris 3 (9.1.4) 256 (13.9) 0.43
Myocardial infarction 4 (12.1) 265 (14.4) 0.71
Hypertension 23 (69.7) 1,031 (56.0) 0.12
Atrial fibrillation 8 (18.2) 318 (18.4) 0.89
Prior/current smoking 21 (63.6) 1,066 (57.9) 0.39
Treatment
IV thrombolysis 7 (21.2) 299 (16.2) 0.44
Carotid endarterectomy 5 (15.2) 64 (3.5) <0.01
Length of index admission, 
median (IQR)
5 (2, 7) 6 (3, 10) 0.01
Discharged to 0.01
Home 22 (66.7) 985 (53.7) 0.13
Home nursing 2 (6.1) 193 (10.5) 0.41
Rehabilitation 0 152 (8.3) 0.09
Nursing home 5 (15.2) 444 (24.2) 0.23
Other department 4 (12.1) 59 (3.2) <0.01
Note. BI, Barthel Index; IQR, interquartile range; mRS, modified Rankin Scale; NIHSS, National 
Institutes of Health Stroke Scale; SD, standard deviation.
Data are expressed as n (%) unless specified.
TA B L E  1  Baseline characteristics of 
population
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recurrence. Of three CE patients, two patients were prescribed an-
ticoagulants after the index event and one after the second event.
Small vessel occlusion was the cause of recurrent stroke in one 
patient. Table 3 shows results from the logistic regression analyses 
where 30-day recurrence vs. no 30-day recurrence is the dependent 
variable. IS or TIA due to SOE and LAA had significantly increased 
risk of 30-day recurrence compared to other etiologies, (HR = 9.72, 
95% CI 1.84–51.3, p < 0.01 and HR = 4.36, 95% CI 2.01–9.47, 
p	<	0.01,	respectively).	Patients	with	a	longer	length	of	stay	≥6	days	
or peripheral artery disease also had significantly higher risk of 30-
day recurrence.
4  | DISCUSSION
We found that 1.8% of our patients was readmitted with a recurrent 
IS or TIA within 30 days. There is scant information on stroke recur-
rence in Norway, but our rate is low compared to many large inter-
national incidence studies (Bravata, Ho, Meehan, Brass, & Concato, 
2007; Lovett et al., 2004; Sacco et al., 1994; Smith, Frytak, Liou, & 
Finch, 2005). Most of these studies included patients dating several 
decades back. Since then, improved secondary prevention may have 
reduced incidence of recurrent stroke and other vascular events 
(Hong, Yegiaian, Lee, Lee, & Saver, 2011). Our low 30-day recurrence 
rate may reflect this progress in stroke medicine. Another explana-
tion might be different definitions of recurrence.
Large artery atherosclerosis had the highest risk of 30-day 
recurrence in our study, as previously reported by other studies 
(Lovett et al., 2004; Petty et al., 2000; Sacco, 1997). Considering 
that CEA is highly effective for reducing recurrent stroke in se-
lected patients with stenosis of the internal carotid artery (Rothwell 
et al., 2003), knowing the risk of early recurrence is important for 
the stroke clinician in order to select and time patients for surgery. 
This is well illustrated in our study, as four of five patients in our 
study found eligible for CEA, suffered a recurrent stroke before 
surgery. On the other hand, peri- and postoperative complications 
after CEA may happen, as one patient in our study suffered a re-
current stroke due to a postoperative intimal flap. Patients with 
atherosclerotic lesions affecting extracranial arteries supplying 
the brain other than the internal carotid are also susceptible to 
atherosclerotic and occlusive disease causing recurrent stroke, 
but these patients have no proven benefit of surgical interven-
tion. TOAST criteria require an intra- or extracranial stenosis of 
>50% to classify a stroke as LAA, a criterion originating from the 
NASCET study in which carotid stenoses were graded from angio-
grams (North American Symptomatic Carotid Endarterectomy Trial 
Collaborators et al., 1991). Since then, growing evidence shows 
that even in nonstenotic intra- or extracranial arteries, high-risk 
atherosclerotic plaques may be the culprit of IS or TIA due to ar-
tery-to-artery embolization (Brinjikji et al., 2016; Kim & Kim, 2014). 
These cases nevertheless often end up being classified as crypto-
genic, which may explain why patients with LAA in our study were 
initially classified as SUE, as more modern imaging techniques like 
emboli detection monitoring and contrast-enhanced ultrasound 
were not routine practice in our stroke unit in the study period.
In our study, a significant part of patients with recurrence had 
intracranial vascular lesions causing recurrent IS or TIA. Intracranial 
stenosis is less common in a more Caucasian population as ours, but 
still has a high risk of causing recurrent stroke (Holmstedt, Turan, 
& Chimowitz, 2013). As intracranial vessels may become stenotic 
or occluded due to both atherosclerotic and embolic disease, we 
did not etiologically group them as LAA, but as a separate group. 
Spontaneous recanalization of emboli in the intracranial arteries will 
often occur, but may happen both in the acute phase and days and 
weeks after the initial stroke (Rha & Saver, 2007). As a result of this, 
it may be difficult to discriminate between LAA and CE as cause of 
an intracranial lesion in the first weeks and months after stroke. All 
patients with intracranial etiology in our study were investigated 
for both extracranial atherosclerotic and cardiac pathology, and 
received medical therapy and risk factor management without any 
mechanical intervention. Patients with severe intracranial vascular 
pathology in our population also seem prone to early recurrence.
Active cancer was the suspected cause of both index and re-
current stroke or TIA in six (18.2%) patients. Cancer cells secrete 
TA B L E  2  Specific etiologies for patients after recurrence
Total (n = 33) 0–30 days %




Intracranial pathology 7 21.2
Cardioembolism (CE) 4 12.1
Small vessel occlusion (SVO ) 1 3
Other demonstrated cause (SOE) 6 18.2
Stroke of unknown etiology 
(SUE)
1 3
TA B L E  3  Logistic regression analysis with 30-day recurrence as 
dependent variable
Odds Ratio 95% CI p
Age, year 1.01 0.98–1.04 0.53




Length of stay 
>6 days
0.90 0.82–0.99 0.03
LAA 4.36 2.01–9.47 <0.01




Note. LAA, Large artery atherosclerosis; mRS, modified Rankin Scale; 
SOC, Stroke of other demonstrated cause; tPA, tissue plasminogen acti-
vator (intravenous thrombolysis).
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procoagulant factors that may induce a hypercoagulable state caus-
ing ischemic stroke and other thromboembolic complications (Bick, 
2003). In clinical practice, cancer-related stroke is considered rare 
and difficult to diagnose (Grisold, Oberndorfer, & Struhal, 2009). 
In our study, several of these patients were initially classified as CE 
because of infarcts in multiple vascular territories. Patients with 
cancer-related coagulopathy may be prone to early recurrence and 
our findings suggest that in patients with recurrent IS or TIA within 
30 days, it may be warranted to screen for a malignancy, especially 
in patients with embolic infarctions. Our numbers are very small 
though and need to be confirmed in larger studies.
Patients with CE and SVO had the lowest rate of 30-day recur-
rence with around 0.5% each. In other studies, early CE stroke re-
currence varies between 1% and 10% (Arboix & Alio, 2010). Many of 
these studies were however performed before anticoagulation was 
implemented as standard practice. Studies investigating the effect 
of aspirin vs. low molecular-weight heparin in the early phase have 
generally shown no benefit of anticoagulation, suggesting that early 
re-embolization is rare (Paciaroni, Agnelli, Micheli, & Caso, 2007). 
Recently published data from our stroke registry show no correlation 
between time to MRI and frequency of multiple acute cerebral in-
farcts in cardio embolic IS, suggesting that cardiogenic emboli seem 
to happen as a shower and not successively (Novotny, Khanevski, 
Thomassen, Waje-Andreassen, & Naess, 2017).
SVO also is reported to have low recurrence rates (Jones et al., 
2013; Lovett et al., 2004; Petty et al., 2000; Sacco, 1997). Although 
the exact pathology of stroke due to SVO is still under debate, the 
process leading to stroke is thought to be intrinsic to the small ves-
sels (Wardlaw, 2005). This would mean that there are fewer sources 
of thrombus or emboli compared with non-SVO stroke. A small meta-
analysis found a lower early risk of recurrence in patients with SVO 
compared to non-SVO stroke (Jackson et al., 2009). In our data, only 
one patient suffered recurrent stroke due to SVO within 30 days.
This study has some limitations. This study is not prospective and 
the estimation of the recurrence rate is based on patients who from 
our stroke unit who sought medical care and were readmitted to our 
stroke unit or other hospital under the Western Norway Regional 
Health Authority. Furthermore, the single-hospital design may cause 
sampling bias and reducing the number of patients with recurrent 
stroke, thus limiting the generalizability of our findings. However, 
we do not have data if patients were hospitalized in other regions 
of Norway or abroad. We cannot exclude that some patients may 
have suffered recurrent IS or TIA without a readmission to the hos-
pital, even if we have a very low admission threshold in suspected 
acute stroke. On the other hand, it provides us with precise clinical 
data as compared to studies using administrative databases for iden-
tification of both recurrent stroke and their causes. In addition, we 
deviated from the TOAST classification in assessment of intracranial 
vascular lesions.
A strength of this study is that it investigates a general stroke 
population by review of medical records which gives a real-life per-
spective on early recurrent stroke. Our single-hospital design gives a 
high possibility of identifying most recurrent stroke cases that were 
hospitalized in our hospital or neighboring hospitals in Western 
Norway. Furthermore, it adds insight into patients groups not pre-
viously well studied for 30-day recurrence, such as patients with 
intracranial vascular lesions and cancer.
In conclusion, most recurrent early IS and TIA cases are caused 
by LAA of extracranial arteries and intracranial atherosclerotic or 
embolic disease. TOAST identified only a proportion of patients ac-
curately at the index event. Patients with recurrent stroke that lack 
conventional risk factors may be considered for cancer screening.
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1  | INTRODUC TION
The	 incidences	 of	 stroke	 and	 post‐stroke	mortality	 have	 declined	
heavily	 in	 high‐income	 countries	 in	 the	 last	 50	years,	 mainly	 be‐
cause	of	 changes	 in	 cardiovascular	 risk	 factors	 and	 improvements	
in	acute	stroke	 treatment.1	Despite	progress	and	declining	 trends,	
recurrent	 stroke	 is	 still	 frequent.2,3	 Studies	 demonstrate	 varying	
recurrence	 rates,	 ranging	 from	 7%‐20%	 at	 1	year	 to	 16%‐35%	 at	
5	years.4,5	Recurrent	 ischemic	stroke	 (IS)	has	been	associated	with	
increased	mortality	and	functional	dependence,6,7	but	this	remains	










2  | MATERIAL S AND METHODS
In	 this	 hospital‐based	 prospective	 cohort,	 all	 patients	 older	
than	 18	years	 admitted	with	 IS	 or	 TIA	 to	 the	 Stroke	Unit	 at	 the	
Department	 of	 Neurology,	 Haukeland	 University	 Hospital,	 be‐
tween	July	1,	2007,	and	December	31,	2013,	were	prospectively	
registered	 in	 the	 Bergen	 NORSTROKE	 Registry.	 Approximately	
275	000	people	 are	 living	 in	 the	 area	 served	by	our	 stroke	unit.	













infarctions	were	defined	as	MRI	 findings	of	 focal	 hyperintensity	
lesions	on	T2	sequences	and	low	signal	 intensity	in	the	presence	
of	 gliosis	 and/or	 cystic	 encephalomalacia	 on	 FLAIR	 sequences.9 
Differentiation	 from	 perivascular	 spaces	 and	 other	 lesions	 was	
made	by	a	neuroradiologist	or	experienced	stroke	clinician	 (HN).	




were	 classified	with	 the	Oxfordshire	 Community	 Stroke	 Project	




event.	 Clinical	 recurrence	 was	 identified	 by	 review	 of	 electronic	
medical	 records	 from	all	 ten	hospitals	under	 the	Western	Norway	
Regional	 Health	 Authority.	 Information	 on	 death	 was	 collected	
electronically	from	the	Norwegian	National	Registry.	Patients	were	
followed	until	 September	1,	2016.	Data	 collection	was	performed	
mainly	 during	 2017.	We	did	 not	 include	 intracerebral	 hemorrhage	







for	 continuous	variables.	Categorical	 variables	 are	presented	as	N	
(%),	and	continuous	variables	are	expressed	as	mean	±	standard	de‐




was	used	 to	estimate	 the	 incidence	of	 all‐cause	mortality.	Factors	
independently	associated	with	IS	or	TIA	recurrence	were	assessed	
with	backward	stepwise	Cox	regression	by	analysis	of	variables	that	















At	 index	 admission,	 714	 (38.1%)	 and	 158	 (8.4)	 patients	 were	
already	 on	 antiplatelet	 agents	 and	 anticoagulation	 agents,	 respec‐
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respectively.	At	index	discharge,	that	increased	to	1331	(71.1%),	1178	
(62.9%),	 and	 247	 (13.2%)	 patients.	 Only	 0.8%	 of	 patients	 (n	=	14)	
were	not	assigned	any	secondary	prevention,	mainly	because	of	con‐
traindications.	Cardioembolism	was	the	most	frequent	determined	






During	 a	mean	 follow‐up	 of	 5.6	years	 (median	 5.5	years,	 max.	
9.2	years,	 8172.8	 person‐years),	 220	 (11.7%)	 patients	 experienced	
241	(87%)	recurrent	IS	and	36	(13%)	TIA.	One	recurrent	event	was	
observed	 in	175	patients,	 two	 in	36	patients,	 three	 in	six	patients,	
and	 four	 in	 three	 patients.	 First	 recurrence	was	 IS	 in	 195	 (88.6%)	
patients	 and	 TIA	 in	 25	 (11.4%)	 patients.	Median	 time	 to	 the	 first	
recurrence	was	436.5	days.	Figure	1	demonstrates	 the	cumulative	
incidence	 function	 adjusted	 for	 age	 (CIF)	 of	 recurrent	 IS	 and	 TIA.	
The	total	cumulative	recurrence	rate	adjusted	for	age	during	follow‐
up	was	14.2%.	After	1	year	and	5	years,	 recurrence	was	observed	
in	 101	 (5.4%)	 and	 201	 (10.7%)	 patients,	 respectively,	 resulting	 in	





Baseline	 characteristics	 of	 the	 cohort	 stratified	 by	 recurrence	
status	at	the	end	of	follow‐up	are	presented	in	Table	1.	Patients	with	
recurrence	had	a	significantly	lower	discharge	mRS	score,	more	fre‐
quently	 a	 history	 of	 previous	 IS	 or	 TIA	 as	well	 as	 chronic	 infarcts	




from	 the	 final	 Cox	 regression	 model.	 History	 of	 hypertension	 at	
index	admission	was	 the	strongest	 independent	 risk	 factor,	with	a	









estimates	 representing	 the	 risk	of	 all‐cause	death	 after	 stroke	are	

















F I G U R E  1  Cumulative	incidence	of	first	recurrence	of	ischemic	stroke	or	TIA








were	 prescribed	 antiplatelet	 or	 anticoagulant	 treatment,	 and	 the	
use	of	 statins	 and	 antihypertensive	 treatment	was	high	 compared	
to	other	studies.14	Finally,	differences	in	populations,	methods,	and	




peting	 risk	of	death	have	reported	1‐	and	5‐year	 incidences	of	 re‐
currence	of	3.6%‐7.7%	and	10.1%‐16.8%.16‐19	Our	 results	 are	 thus	
supporting	newer	data	from	several	other	populations.
Among	 the	 factors	 associated	 with	 recurrence	 in	 our	 study,	
previous	 hypertension	 at	 index	 stroke	 was	 the	 strongest	 one.	
Hypertension	 is	 usually	 considered	 the	 single	most	 important	 risk	


















TA B L E  1  Baseline	characteristics	at	index	stroke	(N,	%)
 
No recurrence Recurrence
N = 1652 N = 220 P
Age	(y),	mean	±	SD 73.0	±	13.8 75.0	±	11.3 0.07








Ischemic	stroke 1468	(88.9) 198	(90.0) 0.61





Cardioembolism 537	(32.5) 67	(30.4) 0.54
Small	vessel	occlusion 187	(11.3) 18	(8.2) 0.16
Other	determined	etiology 27	(1.6) 5	(2.3) 0.49
Undetermined	etiology 694	(42.0) 93	(42.3) 0.94
OCSP	classification
TACI 164	(10.0) 15	(6.9) 0.15
PACI 771	(48.9) 111	(50.9) 0.26
POCI 322	(19.6) 46	(21.1) 0.60
LACI 388	(23.6) 46	(21.1) 0.42
Comorbidities	prior	to	index	event
Prior	ischemic	stroke 199	(12.1) 44	(20.0) <0.01
Prior	TIA 116	(7.0) 28	(12.7) <0.01
Peripheral	artery	disease 117	(7.1) 19	(8.6) 0.40
Coronary	artery	disease 367	(22.2) 51	(23.2) 0.75
Diabetes	mellitus 240	(14.5) 41	(18.6) 0.11
Atrial	fibrillation 476	(28.8) 67	(30.5) 0.61
Hypertension 902	(54.6) 150	(68.2) <0.01





Antiplatelet	agent 1069	(64.7) 159	(72.2) 0.03
Anticoagulation	agent 570	(34.5) 60	(27.3) 0.03








Antihypertensive	drugs 1025	(62.1) 153	(69.6) 0.03





TA B L E  2  Factors	associated	with	recurrence	after	IS	or	TIA,	
(n	=	1621)
 HR 95% CI P
Age,	y 1.02 1.00‐1.03 0.01
Female 0.99 0.74‐1.33 0.96
mRS	score 0.91 0.82‐1.01 0.07
History	of	IS	or	TIA 1.63 1.18‐2.24 <0.01




















tality	 are	not	well	 studied.	 Stroke	 severity	 is	 considered	 the	most	
significant	 factor	 influencing	 short‐	 and	 long‐term	 outcome	 after	















quality	 1‐	 and	5‐year	 recurrence	 and	mortality	 data	 in	 a	 hospital‐
based	 stroke	 population.	 A	 predefined	 investigation	 protocol	 and	
the	use	of	electronic	medical	records	for	identification	of	recurrent	
IS	or	TIA	provide	precise	and	accurate	 clinical	data	on	both	 index	
event	 and	on	 the	 recurrent	 episode	 as	 compared	 to	 studies	 using	
administrative	data.	All	ischemic	stroke	cases	were	confirmed	with	
imaging	studies.	On	this	background,	we	conclude	 that	 the	 risk	of	






F I G U R E  2  Time	do	death	after	index	ischemic	stroke	or	TIA
TA B L E  3   Impact	of	recurrence	on	all‐cause	mortality	after	IS	or	
TIA,	(n	=	1854)
 HR 95% CI P
Recurrent	stroke 2.55 2.04‐3.18 <0.01
Age,	y 1.09 1.08‐1.10 <0.01
Female 0.85 0.72‐1.00 0.06
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